Key Takeaways MITT, SVM and IART are highlighted as stocks to consider after recent broker rating upgrades.MITT's 2026 earnings are expected to rise 26.7%, with broker ratings up 14.3% in four weeks.SVM and IART have projected earnings growth of 30.4% and 9.9%, respectively, plus recent broker rating gains. U.S. equities have shown resilience year to date, though gains have been highly uneven. After recovering from early volatility, markets have moved higher as strong corporate earnings, AI-driven optimism and a still-supportive economy have helped offset broader macro concerns and hawkish Federal Reserve. Investor sentiment has continued to shift with swings in Treasury yields, oil-price volatility, geopolitical risks (particularly Middle East tensions) and evolving tariff policies.
As such, it is not easy for retail investors to select stocks for generating robust returns over time. One way to cut short this task is to follow brokers’ recommendations. In this regard, stocks such as TPG Mortgage Investment Trust, Inc. (MITT - Free Report) , Silvercorp Metals Inc. (SVM - Free Report) and Integra LifeSciences Holdings Corporation (IART - Free Report) are worth considering.
Broker recommendations are typically based on a comprehensive research process that combines direct access to company management, detailed analysis of public disclosures, participation in earnings calls, channel checks, and broader industry. This allows analysts to assess a company’s fundamentals within the context of macroeconomic trends, industry dynamics, competitive positioning, and peer performance, rather than evaluating the business in isolation.
A broker upgrade often reflects a meaningful improvement in an analyst’s outlook for a company. Such a revision may be driven by several factors that may not yet be fully incorporated into consensus estimates or market valuations. Hence, an upgrade can signal a potential inflection point in earnings expectations and investor sentiment.
However, broker upgrades should not be viewed as standalone investment signals. They are most effective when considered alongside other fundamental and valuation factors. As such, broker recommendations should be used as one component of a broader, well-rounded investment decision-making framework.
Selecting the Winning StrategyWe have a screening strategy that may help you identify potential winners.
Broker Rating Upgrades (Four Weeks) of 1% or More: The screen selects stocks that have witnessed broker rating upgrades of 1% or more over the past four weeks.
Current Price Greater Than $5: The stocks must trade above $5.
Average 20-Day Volume Greater Than 100,000: A large trading volume guarantees that the stock is easily tradable.
Zacks Rank Equal to #1 (Strong Buy) or 2 (Buy): Despite good or bad market conditions, stocks with a Zacks Rank #1 or 2 have a proven record of success. You can see the complete list of today’s Zacks #1 Rank stocks here.
VGM Score of A or B: Our research shows that stocks with a VGM Score of A or B, when combined with a Zacks Rank #1 or 2, offer the best upside potential.
3 Stocks With Upgraded Broker Ratings to BuyNew York-based TPG Mortgage is a residential mortgage real estate investment trust. MITT’s investment portfolio comprises residential investments, non-agency residential mortgage-backed securities, commercial loans and commercial mortgage-backed securities.
MITT’s 2026 earnings are expected to increase 26.7% year over year. TPG Mortgage, which currently carries a Zacks Rank #2, has witnessed a 14.3% upward revision in broker ratings over the past four weeks.
Silvercorp Metals, based in Canada, acquires, explores, develops and mines mineral properties in China. SVM explores for copper, silver, gold, lead and zinc metals.
Silvercorp Metals’ fiscal 2027 earnings are projected to jump 30.4% on a year-over-year basis. SVM, sporting a Zacks Rank #1 at present, has witnessed a 16.7% upward revision in broker ratings over the past four weeks.
Headquartered in Plainsboro, NJ, Integra LifeSciences is one of the leading names in regenerative medicine. IART develops, manufactures and markets surgical implants and medical instruments.
Integra LifeSciences’ 2026 earnings are expected to rise 9.9% year over year. IART, which currently carries a Zacks Rank #2, has witnessed a 9.1% upward revision in broker ratings over the past four weeks.
BOISE, Idaho & NEW YORK & CHICAGO & LONDON & HONG KONG--(BUSINESS WIRE)--Clearwater Analytics (NYSE: CWAN) today released Credit Where It’s Due: The Persistent Rise of Private Credit, its first comprehensive study of how private credit has reshaped institutional portfolios.
The report draws on holdings and transactions data from the Clearwater platform, which spans $10 trillion in institutional assets across 60 asset classes. It documents private credit exposure, examines how the asset class has contributed to returns, and identifies where investment risks concentrate. The findings challenged a narrative centered on systemic contagion. Instead it found the systemic risks were idiosyncratic, concentrated on specific balance sheets that are largely hidden from investors without the right infrastructure.
“At Clearwater, we are no strangers to the rise of private credit. Assets on our platform have grown nearly 20% over the last two years alone,” said Kirat Singh, President of Risk and Alternative Assets at Clearwater Analytics. “This report was born from what we see every day in our data, and it aims to bring a grounded, differentiated perspective to a conversation that is too often driven by headlines rather than evidence.”
Benchmarking private credit has proven difficult. The asset class lacks the standardized reporting infrastructure of public markets, and long-term trend data on institutional allocations have been hard to come by. Clearwater’s platform reconciles holdings daily at the security level across a broad institutional base, making it possible to document how private credit is allocated across insurers, corporate treasurers, and private wealth investors, what it has contributed to returns at a subclass level, and where exposures concentrate.
The data shows how much ground private credit has gained. Median insurer allocations have grown 110% since 2021, reaching 9% of total portfolio assets. Corporate treasurers, who held little private credit a few years ago, have climbed to a median allocation of 2%. Liability structure, regulatory treatment, and access to origination all shape the allocation.
Private credit lacks the contagion mechanisms that made 2008 systemic, without the interconnected leverage and structured exposure that caused cascading failures. Instead, the risks are idiosyncratic, concentrated on individual balance sheets, often across multiple managers, vintage years, and fund vehicles, and largely invisible without the right infrastructure. The report coins a term for this pattern: cross-contamination risk.
Tracking those exposures requires infrastructure that most investors have had to piece together from multiple systems. Technology is closing that gap, providing the look-through visibility and daily reconciliation needed to make idiosyncratic risk manageable rather than invisible.
“Private credit has earned its place in institutional portfolios, and the performance data bears that out,” said Matthew Vegari, Head of Research at Clearwater Analytics. “What the market is still catching up to is the operational and analytical infrastructure needed to manage it. Investors who can see how their exposures interact across a full balance sheet will be better positioned to act on that information, and to manage risk as a source of competitive advantage rather than uncertainty.”
The full report, Credit Where It’s Due: The Persistent Rise of Private Credit, is available at cwan.com/Research-Desk.
About Clearwater Analytics
Clearwater Analytics is transforming investment management with the industry’s most comprehensive cloud-native platform for institutional investors across global public and private markets. While legacy systems create risk, inefficiency, and data fragmentation, Clearwater’s single-instance, multi-tenant architecture delivers real-time data and AI-driven insights throughout the investment lifecycle. The platform eliminates information silos by integrating portfolio management, trading, investment accounting, reconciliation, regulatory reporting, performance, compliance, and risk analytics in one unified system. Serving leading insurers, asset managers, hedge funds, banks, corporations, and governments, Clearwater supports over $10 trillion in assets globally. Learn more at www.cwan.com.
Clearwater Analytics (NYSE: CWAN) today released Credit Where It’s Due: The Persistent Rise of Private Credit, its first comprehensive study of how private credit has reshaped institutional portfolios.
The report draws on holdings and transactions data from the Clearwater platform, which spans $10 trillion in institutional assets across 60 asset classes. It documents private credit exposure, examines how the asset class has contributed to returns, and identifies where investment risks concentrate. The findings challenged a narrative centered on systemic contagion. Instead it found the systemic risks were idiosyncratic, concentrated on specific balance sheets that are largely hidden from investors without the right infrastructure.
“At Clearwater, we are no strangers to the rise of private credit. Assets on our platform have grown nearly 20% over the last two years alone,” said Kirat Singh, President of Risk and Alternative Assets at Clearwater Analytics. “This report was born from what we see every day in our data, and it aims to bring a grounded, differentiated perspective to a conversation that is too often driven by headlines rather than evidence.”
Benchmarking private credit has proven difficult. The asset class lacks the standardized reporting infrastructure of public markets, and long-term trend data on institutional allocations have been hard to come by. Clearwater’s platform reconciles holdings daily at the security level across a broad institutional base, making it possible to document how private credit is allocated across insurers, corporate treasurers, and private wealth investors, what it has contributed to returns at a subclass level, and where exposures concentrate.
The data shows how much ground private credit has gained. Median insurer allocations have grown 110% since 2021, reaching 9% of total portfolio assets. Corporate treasurers, who held little private credit a few years ago, have climbed to a median allocation of 2%. Liability structure, regulatory treatment, and access to origination all shape the allocation.
Private credit lacks the contagion mechanisms that made 2008 systemic, without the interconnected leverage and structured exposure that caused cascading failures. Instead, the risks are idiosyncratic, concentrated on individual balance sheets, often across multiple managers, vintage years, and fund vehicles, and largely invisible without the right infrastructure. The report coins a term for this pattern: cross-contamination risk.
Tracking those exposures requires infrastructure that most investors have had to piece together from multiple systems. Technology is closing that gap, providing the look-through visibility and daily reconciliation needed to make idiosyncratic risk manageable rather than invisible.
“Private credit has earned its place in institutional portfolios, and the performance data bears that out,” said Matthew Vegari, Head of Research at Clearwater Analytics. “What the market is still catching up to is the operational and analytical infrastructure needed to manage it. Investors who can see how their exposures interact across a full balance sheet will be better positioned to act on that information, and to manage risk as a source of competitive advantage rather than uncertainty.”
The full report, Credit Where It’s Due: The Persistent Rise of Private Credit, is available at cwan.com/Research-Desk.
About Clearwater Analytics
Clearwater Analytics is transforming investment management with the industry’s most comprehensive cloud-native platform for institutional investors across global public and private markets. While legacy systems create risk, inefficiency, and data fragmentation, Clearwater’s single-instance, multi-tenant architecture delivers real-time data and AI-driven insights throughout the investment lifecycle. The platform eliminates information silos by integrating portfolio management, trading, investment accounting, reconciliation, regulatory reporting, performance, compliance, and risk analytics in one unified system. Serving leading insurers, asset managers, hedge funds, banks, corporations, and governments, Clearwater supports over $10 trillion in assets globally. Learn more at www.cwan.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260624790679/en/
Morningstar Houlihan CLO Indexes, to be introduced later this year, are designed to improve transparency and consistency in rapidly growing but still underserved market for CLO indexes, data, and research.
CHICAGO--(BUSINESS WIRE)--Morningstar, Inc. (NASDAQ: MORN), a leading provider of independent investment insights and market data, today announced a strategic collaboration with leading global investment bank Houlihan Lokey (NYSE: HLI) to develop a new suite of daily valuation indexes to help investors measure and invest in collateralized loan obligations (CLOs).
Through this new initiative, Morningstar Indexes will work with Houlihan Lokey’s Portfolio Valuation and Fund Advisory Services team to develop the Morningstar Houlihan CLO Indexes. The index series will combine Morningstar’s design and governance with Houlihan Lokey’s valuation framework and credit market expertise to address the growing need for reliable benchmarks in the rapidly expanding CLO market.
CLOs have evolved in the last decade from a niche structured product into a trillion-dollar global asset class, driven by growing investor demand for yield, floating-rate exposure, and diversified credit alternatives. Industry experts estimate that the global CLO market, which has grown into more than $1.5 trillion in assets, could exceed $3 trillion in investor assets by 2030.*
As the market has expanded, however, the availability of consistent benchmarks and transparent, frequent pricing has not kept pace, making it harder for investors to assess performance and risk with confidence. The new indexes will establish a new benchmark standard for the CLO market, enabling investors to better assess performance, manage risk, and navigate an increasingly important segment of private credit.
Sanjay Arya, head of innovation for Morningstar Indexes, commented: “We’re thrilled to join forces with Houlihan Lokey, the market leader in valuations for illiquid assets and a recognized authority in CLO pricing and credit market analytics, to address a clear investor need. Alongside our existing category leading leveraged loan indexes, this collaboration will enable Morningstar to introduce a new family of benchmarks in one of the fastest-growing segments of private credit and bring more transparency to private markets.”
Dr. Cindy Ma, managing director and global head of portfolio valuation and fund advisory services for Houlihan Lokey, commented: “The growth of the CLO market, a highly specialized asset class, has outpaced the development of high-quality investor tools. As complexity and assets rise, data, transparency, and advanced analytics are becoming critical competitive differentiators for investors operating in this market. We’re excited to work with Morningstar Indexes to better serve the rapidly growing CLO investor market.”
About Morningstar Indexes
Morningstar Indexes was built to keep up with the evolving needs of investors—and to be a leading-edge advocate for them. Morningstar's rich heritage as a transparent, investor-focused leader in data and research uniquely equips Morningstar Indexes to support individuals, institutions, wealth managers and advisors in navigating investment opportunities across all major asset classes, styles, and strategies. In February 2026, the acquisition of CRSP brought the CRSP Market Indexes – benchmarks for over $3 trillion in US equities – into the Morningstar Indexes family. Additionally, CRSP’s Research Data Products, renowned for their academic rigor, historical depth and accuracy, further enhances Morningstar’s equity research and data capabilities. This powerful combination unites two trusted sources of market insight, reinforcing a shared commitment to transparency, quality and investor-focused solutions. Please visit indexes.morningstar.com for more information.
About Houlihan Lokey
Houlihan Lokey, Inc. is a leading global investment bank recognized for delivering independent strategic and financial advice to corporations, financial sponsors, and governments. With uniquely deep industry expertise, broad international reach, and a partnership approach rooted in trust, the firm provides innovative, integrated solutions across mergers and acquisitions, capital solutions, financial restructuring, and financial and valuation advisory. Our unmatched transaction volumes provide differentiated, data-driven perspectives that help our clients achieve their most critical goals. To learn more about Houlihan Lokey, please visit HL.com.
Houlihan Lokey’s Portfolio Valuation and Fund Advisory Services practice is a leading advisor to many of the world’s largest asset managers who rely on our (i) strong reputation with regulators, auditors, and investors; (ii) private company, structured product, and derivative valuation experience; and (iii) independent voice.
About Morningstar, Inc.
Morningstar, Inc. is a leading provider of independent investment insights in North America, Europe, Australia, and Asia. The Company offers an extensive line of products and services for individual investors, financial advisors, asset managers and owners, retirement plan providers and sponsors, institutional investors in the debt and private capital markets, and alliances and redistributors. Morningstar provides data and research insights on a wide range of investment offerings, including managed investment products, publicly listed companies, private capital markets, debt securities, and real-time global market data. Morningstar also offers investment management services through its investment advisory subsidiaries, with approximately $370 billion in assets under management and advisement (AUMA) as of March 31, 2026. The Company operates through wholly- or majority-owned subsidiaries in 32 countries. For more information, visit www.morningstar.com/company.
, /PRNewswire/ -- Broadridge Financial Solutions, Inc. (NYSE: BR) today announced that Mark Nichols has joined the company as Co-President, Digital Assets, a move that reinforces Broadridge's ongoing commitment to modernize financial market infrastructure and expand its digital asset capabilities. In his role, Nichols will spearhead Broadridge's strategy, product development, and execution across the tokenization and digital asset arena, along with Co-President German Soto Sanchez.
Broadridge Names Mark Nichols Co-President of Digital Assets "Digital assets are a critical part of the next generation of market infrastructure, and Broadridge is delivering a suite of solutions that support clients and investors in the trading and on-chain governance of tokenized securities with institutional grade scalability, accuracy, compliance, and workflows," said Tim Gokey, CEO of Broadridge. "Mark's combination of strategic vision, market infrastructure expertise, and deep knowledge of tokenization will help us accelerate those efforts and support the adoption of tokenized securities."
Nichols joins Broadridge from Ernst & Young US LLP, where as a Partner, he co-led EY's digital asset consulting business and led its market infrastructure consulting practice. Earlier in his career, he led product across FCM, collateral, and funding within Deutsche Bank's fixed income business.
"Broadridge is uniquely positioned to help shape how digital assets are integrated into the financial system at scale given the important role it plays in supporting trading and governance," said Mark Nichols, Co-President, Digital Assets at Broadridge. "I'm excited to help deliver innovative solutions that will better enable clients to scale and adapt to the future of on-chain finance and tokenization."
About Broadridge's Tokenization Solutions
Broadridge enables on-chain proxy voting and governance, digital asset infrastructure including post trade, wallets and custody, and the scaling of digital asset capabilities across multiple asset classes. Through these innovations, Broadridge is helping financial institutions unlock the next era of digital assets investing.
Broadridge's Distributed Ledger Repo (DLR) solution is the world's largest institutional platform for settling tokenized real assets, tokenizing approximately over $365 billion a day. As tokenization gains momentum across financial services, Broadridge is meeting the complexity of operating across traditional and digital ecosystems with established scale, critical market knowledge, and technological expertise
About Broadridge
Broadridge Financial Solutions (NYSE: BR) is a global technology leader with trusted expertise and transformative technology, helping clients and the financial services industry operate, innovate, and grow. We power investing, governance, and communications for our clients – driving operational resiliency, elevating business performance, and transforming investor experiences.
Our technology and operations platforms process and generate over 7 billion communications annually and underpin the daily average trading of over $15 trillion in tokenized and traditional securities globally. A certified Great Place to Work®, Broadridge is part of the S&P 500® Index, employing over 15,000 associates in 21 countries.
For more information about us, please visit www.broadridge.com
Key Takeaways Sterling ended Q1 2026 with a record $3.8B signed backlog and $5.15B combined backlog.MasTec posted a record $20.3B backlog, with Q1 2026 adjusted EBITDA up 73% year over year.STRL's 2026 and 2027 EPS estimates rose Y/Y, outpacing projected growth for MTZ. The surge in U.S. energy, communications and large-scale development infrastructure spending is being driven by several structural trends that are likely to persist for years rather than quarters. With the explosion in AI-related data center development, the expansion of generation, transmission and distribution network projects has accelerated. Amid this backdrop, infrastructure companies such as Sterling Infrastructure, Inc. (STRL - Free Report) and MasTec, Inc. (MTZ - Free Report) are direct beneficiaries.
Sterling is a diversified U.S. infrastructure services company, which is favoring from the multi-year demand growth visibility and is currently focused on stabilizing its market footing and prospects in the upcoming term through strategic organic or inorganic business efforts. Meanwhile, MasTec, which engages in the engineering, building, installation, maintenance and upgrade of energy, communication and utility, is working on expanding its margins and improving execution.
Let’s closely compare the fundamentals of the two infrastructure stocks to determine which one is a better investment now.
The Case for Sterling StockThis Texas-based infrastructure services provider started its 2026 journey with phenomenal financial performance amid favorable market trends. As mission-critical activity in data centers, advanced manufacturing and semiconductors grows, it is creating numerous project opportunities for the company. STRL ended first-quarter 2026 with a record $3.8 billion signed backlog and $5.15 billion combined backlog, representing year-over-year growth of 78% and 131%, respectively. Besides, its pipeline of high-probability future phase opportunities now exceeds $1.3 billion, bringing its visible work pool close to $6.5 billion. STRL’s CEC business has secured several large project awards since its acquisition, contributing $1.2 billion to the total backlog.
The company’s inorganic moves are encouraging, as the acquired companies not only expand its market footing but also diversify its service portfolio and increase its growth trajectory. Sterling's acquisition of CEC has enhanced its ability to offer integrated site development and mission-critical electrical services under one roof. This strategy improves project coordination, execution efficiency and margin potential while making STRL a more valuable partner for hyperscale data center and semiconductor customers.
Moreover, the recent acquisition of Stone Ridge Contracting, LLC expanded STRL’s geographic footprint in the Pacific Northwest and Texas. Stone Ridge is a Pocatello, ID-based heavy civil, concrete and construction management services provider with services stretching across sectors, including data centers, mining and industrial infrastructure. In 2026, Stone Ridge is expected to generate revenues between $180 million and $200 million, with EBITDA margins projected to be in the mid-teens.
Alongside investing in growth opportunities, Sterling remains committed to enhancing shareholder value through disciplined capital deployment. It repurchased $12.3 million of shares during the first quarter of 2026, reflecting management's confidence in the business and its long-term earnings potential. STRL retains $362 million of share repurchase authorization and intends to be opportunistic after the first quarter’s buyback. Management also notes a richer pipeline of high-quality M&A targets compared with a year ago and cites significant balance sheet firepower. This setup supports selective acquisitions, internal capacity adds and buybacks without stressing leverage, helping cushion timing variability as backlog converts.
The Case for MasTec StockMasTec is also gaining from sustained demand across multiple infrastructure end markets. Communications growth is supported by rising data consumption, fiber deployment and multiyear broadband initiatives, including BEAD funding. Power Delivery demand is driven by grid modernization, system hardening and rising electricity needs, with data centers expected to materially increase power consumption. Clean Energy and Infrastructure is seeing growth across renewables, industrial projects and mission-critical facilities, including data centers. This diversification reduces reliance on any single market and supports more stable long-term growth.
Backlog reached a record $20.3 billion in the first quarter of 2026, increasing approximately 7% sequentially and 28% year over year, supported by a 1.4x book-to-bill ratio. Management highlighted that the backlog does not fully capture ongoing negotiations and verbal awards, indicating additional upside potential. It also highlighted growing opportunities in fiber interconnectivity, transmission infrastructure and turnkey data center construction, positioning MasTec at the center of several multiyear infrastructure trends.
In the first quarter of 2026, MTZ’s adjusted EBITDA increased 73% year over year, with a margin expansion of 170 basis points. Power Delivery and Pipeline segments showed notable margin improvements, supported by better execution and project performance. MasTec expects continued margin expansion across segments in 2026, with full-year EBITDA guidance raised to approximately $1.5 billion and margins improving modestly. This reflects a better project mix, pricing improvements and operational discipline.
However, variability in project timing, dwindling cash flow, increasing inflation risks and global political unrest are proving to be near-term growth restrictions for the company. MasTec operates in markets influenced by government policy and regulatory approvals. Renewable energy investment remains tied to policy frameworks and potential changes to incentive structures could impact project activity in Clean Energy and Infrastructure. These factors introduce uncertainty into project pipelines despite favorable long-term demand trends.
Stock Performance & ValuationAs witnessed from the chart below, in the year-to-date period, Sterling’s share price performance has significantly outperformed MasTec's and the broader Construction sector.
Image Source: Zacks Investment Research
Considering valuation, over the last five years, Sterling has been trading above MasTec on a forward 12-month price-to-earnings (P/E) ratio basis.
Image Source: Zacks Investment Research
Overall, from these technical indicators, it can be deduced that STRL stock offers an accelerating growth trend but with a premium valuation, while MTZ stock offers a diminishing growth trend with a discounted valuation.
Comparing EPS Estimate Trends: STRL vs. MTZThe Zacks Consensus Estimate for STRL’s 2026 and 2027 earnings has trended upward in the past 30 days to $19.31 per share and $27.43 per share, respectively. The estimates for 2026 and 2027 imply year-over-year growth of 77.5% and 42.1%, respectively.
STRL's EPS Trend
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for MTZ’s 2026 and 2027 earnings has trended upward in the past 60 days to $8.86 per share and $11.77 per share, respectively. The revised estimated figures for 2026 and 2027 imply 35.3% and 32.8% year-over-year growth, respectively.
MTZ's EPS Trend
Image Source: Zacks Investment Research
Return on Equity (ROE) of STRL & MTZ StocksSterling’s trailing 12-month ROE of 37.02% significantly exceeds MasTec’s average, underscoring its efficiency in generating shareholder returns.
Image Source: Zacks Investment Research
Investment Decision: Choosing Between STRL Stock & MTZ StockBoth Sterling and MasTec are benefiting from the multiyear U.S. infrastructure buildout tied to AI data centers, power demand, broadband expansion and industrial development. However, based on the growth metrics, earnings momentum and technical indicators, Sterling appears to have the stronger investment case today.
Sterling’s exceptional execution efforts and backlog momentum, supported by strong demand from data centers, semiconductor fabs and advanced manufacturing projects, alongside the acquisitions of CEC and Stone Ridge, boost its upcoming growth prospects. Management’s raised 2026 outlook, expanding buyback authorization and robust M&A pipeline further reinforce confidence in long-term growth. Additionally, EPS estimates imply growth of 77.5% in 2026 and 42.1% in 2027, while ROE stands at an impressive 37%.
MasTec also remains well positioned, with a record $20.3 billion backlog, improving margins and exposure to communications, power delivery and clean energy markets. Earnings estimates are moving higher, and valuation remains more attractive than Sterling’s. However, project timing risks, regulatory uncertainty surrounding renewable energy investments and weaker cash-flow trends temper the near-term outlook.
That said, Sterling’s superior stock performance, faster earnings growth, stronger ROE and clearer exposure to high-growth AI infrastructure markets outweigh its premium valuation. Thus, with a Zacks Rank #1 (Strong Buy) versus MasTec’s Zacks Rank #3 (Hold), STRL stock emerges as the better stock to buy now for investors seeking growth, while MTZ stock may appeal more to value-oriented investors willing to accept a slower growth trajectory. You can see the complete list of today’s Zacks #1 Rank stocks here.
Key Takeaways Newell's core sales fell 3.5% in Q1 but improved sequentially and beat management's expectations.Six of Newell's top 10 brands gained share, while six delivered year-over-year POS growth in Q1.Newell plans 25 major innovations in 2026 and expects core sales growth to return in Q2. Newell Brands Inc.’s (NWL - Free Report) turnaround strategy appears to be gaining traction, supported by improving consumer demand, stronger point-of-sale trends and market share gains across several key brands. Although core sales remained negative in the first quarter, management’s commentary suggests that the company’s renewed focus on innovation, advertising investments and retail execution is beginning to translate into better business performance, raising the question of whether Newell is approaching a sustainable growth inflection point.
The numbers suggest meaningful progress. First-quarter core sales declined 3.5% year over year, but the result exceeded management’s expectations and marked a sequential improvement from prior quarters. Six of Newell’s top 10 brands gained market share during the quarter, while six brands also posted year-over-year point-of-sale growth for the first time in more than four years. The Learning & Development segment returned to growth, driven by a 4.9% increase in the Baby business. Additionally, the company benefited from a $25 million net pricing advantage tied to improved customer program management, helping normalize operating margin and expand it by 30 basis points to 4.8%.
A key driver behind the improving sales trajectory is Newell’s strengthened innovation pipeline. The company plans to launch 25 Tier 1 and Tier 2 innovations in 2026, up from 18 in the previous year, with products spanning all business segments. Management noted strong early consumer response to innovations such as Graco’s new car seats and Coleman’s Snap 'N Go cooler. Coupled with higher advertising and promotional spending, these initiatives are supporting stronger retailer relationships, distribution gains and shelf placement opportunities, which should provide additional sales momentum throughout the year.
Despite encouraging signs, challenges remain. Commodity inflation, particularly higher resin and transportation costs, continues to pressure profitability, while consumer spending trends remain uneven across income groups. Nevertheless, Newell’s reduced exposure to China sourcing, expanded domestic manufacturing capabilities and disciplined cost-management efforts position the company well to navigate these headwinds. With management now expecting a return to core sales growth in the second quarter and raising its full-year sales outlook, the turnaround story appears increasingly credible, though sustained execution will be critical to proving that the recovery is durable.
Newell’s Zacks Rank & Share Price PerformanceShares of this Zacks Rank #3 (Hold) company have rallied 43.8% in the past three months, outperforming both the industry and the broader Consumer Staples sector, which rose 0.1% and 2.9%, respectively.
NWL Stock's Past Three-Month Performance
Image Source: Zacks Investment Research
Is NWL a Value Play Stock?Newell currently trades at a forward 12-month P/E ratio of 8.59X, which is notably lower than the industry multiple of 17.84X and the sector average of 16.47X. This valuation positions the stock at a modest discount relative to both its direct peers and the broader consumer staples sector.
NWL P/E Ratio (Forward 12 Months)
Image Source: Zacks Investment Research
Stocks to ConsiderThe Chefs' Warehouse, Inc. (CHEF - Free Report) distributes specialty food and center-of-the-plate products in the United States, the Middle East and Canada. At present, CHEF sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The consensus estimate for Chefs' Warehouse’s current fiscal-year sales and earnings implies growth of 8.3% and 24.7%, respectively, from the year-ago reported figures. CHEF delivered a trailing four-quarter earnings surprise of 28.9%, on average.
United Natural Foods, Inc. (UNFI - Free Report) distributes natural, organic, specialty, produce and conventional grocery and non-food products in the United States and Canada. At present, United Natural carries a Zacks Rank of 2 (Buy). UNFI delivered a trailing four-quarter earnings surprise of 29.9%, on average.
The consensus estimate for United Natural’s current fiscal-year earnings implies growth of 254.9% from the year-ago figures.
Mama's Creations, Inc. (MAMA - Free Report) manufactures and markets fresh deli-prepared foods in the United States. At present, MAMA has a Zacks Rank of 2. Mama's Creations delivered a trailing four-quarter earnings surprise of 129.2%, on average.
The consensus estimate for Mama's Creations’ current fiscal-year sales and earnings implies growth of 30% and 73.3%, respectively, from the year-ago figures.
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.
It also includes access to the Zacks Style Scores.
What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.
Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.
The Style Scores are broken down into four categories:
Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.
Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.
Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.
Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +24% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.
That's where the Style Scores come in.
To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.
As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.
For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: FactSet Research (FDS - Free Report) Headquartered in Norwalk, CT, FactSet Research Systems Inc. is a leading provider of integrated financial information, analytical applications and industry-leading service for the global investment community. Through its analytics, service, content, and technology, the company offers information to investment professionals like portfolio managers, wealth managers, research and performance analysts, risk managers, research professionals, investment research professionals, investment bankers, risk and performance analysts, wealth advisors and fixed income professionals. By integrating datasets and analytics across asset classes with client data, FactSet supports the workflow of both buy-side and sell-side clients. Through its wide application suite, FactSet offers tools and resources that include company and industry analyses, full screening tools, portfolio analysis, risk profiles, alpha-testing, portfolio optimization and research management solutions. The company derives revenues from subscriptions to products and services such as workstations, analytics, enterprise data, research management, and trade execution.
FDS is a #2 (Buy) on the Zacks Rank, with a VGM Score of A.
It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 12.38; value investors should take notice.
For fiscal 2026, one analyst revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.01 to $17.66 per share. FDS boasts an average earnings surprise of +0.4%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, FDS should be on investors' short list.
FactSet Research Systems Inc. (NYSE:FDS) will release its third quarter earnings report after the closing bell on Wednesday, July 1.
Analysts expect the Norwalk, Connecticut-based company to report quarterly earnings of $4.45 per share, up from $4.27 per share in the year-ago period. The consensus estimate for FactSet Research’s quarterly revenue is $617.59 million. It reported $585.52 million last year, according to Benzinga Pro.
On May 5, FactSet raised its quarterly dividend from $1.10 per share to $1.16 per share.
FactSet Research shares fell 0.2% to close at $218.15 on Tuesday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.
Considering buying FDS stock? Here’s what analysts think:
Photo via Shutterstock
Market News and Data brought to you by Benzinga APIs
The market expects FactSet Research (FDS - Free Report) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended May 2026. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.
The earnings report, which is expected to be released on July 1, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.
While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.
Zacks Consensus EstimateThis financial data firm is expected to post quarterly earnings of $4.44 per share in its upcoming report, which represents a year-over-year change of +4%.
Revenues are expected to be $617.19 million, up 5.4% from the year-ago quarter.
Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 0.03% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts.
Price, Consensus and EPS Surprise
Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for FactSet?For FactSet, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -1.85%.
On the other hand, the stock currently carries a Zacks Rank of #2.
So, this combination makes it difficult to conclusively predict that FactSet will beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that FactSet would post earnings of $4.37 per share when it actually produced earnings of $4.46, delivering a surprise of +2.06%.
Over the last four quarters, the company has beaten consensus EPS estimates two times.
Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
FactSet doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
Key Takeaways ACHC raised full-year Adjusted EBITDA guidance after Q1 2026 revenues rose 7.6% to $828.8 million.ACHC is prioritizing returns from existing assets and plans 2026 capital spending of $255-$280 million.ACHC is resolving disputes, strengthening compliance, and improving retention. Acadia Healthcare Company, Inc. (ACHC - Free Report) demonstrates how a mission-driven healthcare company can create long-term shareholder value. As the largest standalone behavioral health provider in the United States, operating 275 facilities and more than 12,400 beds across 40 states, Acadia plays a critical role in addressing the nation's growing mental health and addiction treatment needs. Following a challenging period marked by regulatory scrutiny and industry-wide pressures, it has focused on rebuilding operational strength and restoring investor confidence.
Over the past year, management has taken meaningful steps to protect shareholder value. Acadia resolved some legacy billing disputes, worked toward strengthening compliance standards and improving workforce retention, and brought back experienced industry leader Debbie Osteen as CEO. These actions signal a commitment to accountability, operational discipline and long-term value creation.
Acadia's strategy has also evolved. Rather than pursuing growth, it has shifted toward maximizing returns from its existing footprint, limiting planned 2026 capital expenditures to a range of $255 million to $280 million. This strategic shift is evident in the company’s recent results, with first-quarter 2026 revenues rising 7.6% year over year to $828.8 million and management raising its full-year adjusted EBITDA guidance from $575-$610 million to $580-$615 million.
Demand for mental health and addiction treatment continues to rise, supported by growing awareness and significant unmet patient needs. While some historical expansions weighed on returns, many recently developed facilities are approaching maturity. Acadia now has an opportunity to convert years of investment into improved profitability, creating a potential turnaround opportunity for long-term investors.
How Are Competitors Faring?Peers such as Universal Health Services, Inc. (UHS - Free Report) and LifeStance Health Group, Inc. (LFST - Free Report) are also pursuing growth and operational efficiency initiatives.
Universal Health Services is increasingly focused on extracting greater value from its behavioral health network. Alongside efforts to improve occupancy and outpatient growth, UHS recently announced its $835 million acquisition of Talkspace to expand patient access and broaden treatment options.
LifeStance Health continues to strengthen its outpatient mental health platform through clinician expansion and technology-enabled care, reflecting LFST’s efforts to capture a bigger share of the growing demand for behavioral health services.
ACHC’s Price Performance, Valuation & EstimatesShares of Acadia have gained 20.9% over the past year compared to the industry’s 8.4% decline over the same period.
Image Source: Zacks Investment Research
From a valuation standpoint, ACHC trades at a forward price-to-earnings ratio of 15.71X, up from the industry average of 8.45X. ACHC carries a Value Score of C.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for ACHC’s 2026 earnings is pegged at $1.50 per share, which has moved 1 cent up in the past 60 days.
Image Source: Zacks Investment Research
Acadia currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Clean Energy Fuels Corp. (NASDAQ: CLNE), the country’s leading provider of renewable natural gas (RNG) for the transportation market, today announced the appointment of Bart Frabotta as Chief Operating Officer (COO). Frabotta will oversee Clean Energy’s operations division and will also become one of the company’s named executive officers.
"I will look to Bart to take the lead in two of my top priorities – becoming a technology-forward company implementing all the advantages AI has to offer, and making Clean Energy a low-cost company while still accelerating growth."
Share Frabotta joined Clean Energy in 2010 and has served as Group Vice President of Operations since 2021. He has over 20 years of leadership experience in energy infrastructure, construction, operations, technology, and industrial services.
Stepping into the role as COO, he will lead company-wide operational functions, including station operations, RNG and liquefied natural gas (LNG) production, engineering and construction, field services, supply chain, EHS, IT, and AI initiatives. He will also oversee key business transformation programs.
“Since joining Clean Energy, Bart has been tasked with more and more responsibilities and has always overperformed,” said Clay Corbus, President and CEO of Clean Energy. “His leadership has driven meaningful change in reliability, efficiency, and cost structure across our station network. I will look to Bart to take the lead in two of my top priorities – becoming a technology-forward company implementing all the advantages AI has to offer, and making Clean Energy a low-cost company while still accelerating growth.”
“Taking on the role of COO at such an important time for Clean Energy and the broader alternative fuels industry is both an honor and a tremendous opportunity,” said Frabotta. “We have an incredibly talented team across the organization, and I’m excited to continue working alongside them to enhance our capabilities, deliver reliable solutions, and help drive our company into its next phase of growth.”
About Clean Energy
Clean Energy Fuels Corp. is the country’s largest provider of the cleanest fuel for the transportation market. Our mission is to decarbonize transportation through the development and delivery of renewable natural gas (RNG), a sustainable fuel derived by capturing methane from organic waste. Clean Energy allows thousands of vehicles, from airport shuttles to city buses to waste and heavy-duty trucks, to reduce their amount of climate-harming greenhouse gas. We operate a vast network of fueling stations across the U.S. and Canada as well as RNG production facilities at dairy farms. Visit www.cleanenergyfuels.com and follow @ce_renewables on X and LinkedIn.
Forward Looking Statements
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, that involve risks, uncertainties and assumptions, including without limitation statements about the appointment of Bart Frabotta as Clean Energy’s Chief Operating Officer, and plans, beliefs, and expectations related thereto. The forward-looking statements made herein speak only as of the date of this press release and, unless otherwise required by law, Clean Energy undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. Additionally, the reports and other documents Clean Energy files with the SEC (available at www.sec.gov) contain risk factors, which may cause actual results to differ materially from the forward-looking statements contained in this news release.
Native AI agents added to RingCX workflows giving businesses automated outreach, intelligent handoffs, and more
LAS VEGAS--(BUSINESS WIRE)--RingCentral, Inc. (NYSE: RNG) today announced the expansion of AIR Pro™ to deliver agentic AI capabilities across the RingCentral customer engagement portfolio. The expansion includes new capabilities within RingCX™ that help businesses with end-to-end customer resolution, automated outreach, and intelligent hand-offs. These enhancements also strengthen how customer context is captured and carried within RingCX. When a conversation transfers to a live agent, that agent has a more complete picture, including prior interactions, data from connected systems via APIs, and relevant recordings — without having to ask the customer to repeat themselves. The context layer continuously informs itself, getting smarter with every interaction.
“RingCentral offers the broadest range of customer engagement solutions that address both informal and formal contact center requirements. Our announcement today is about expanding AIR Pro and adding key updates to RingCX as we make progress toward our vision of AI agents and humans working together,” said Jim Dvorkin, SVP of Customer Experience Products at RingCentral. “Our innovations for RingCX continue to be well received by our customers. The addition of native AI agents, along with autonomous outreach, intelligent handoffs, and our AI powered workflow builder for RingCX helps businesses improve customer experiences and achieve measurable results.”
Where Humans and AI Agents Work Together
Highlighted at Customer Contact Week (CCW) Las Vegas 2026, RingCentral rolled out the following updates:
Native AI Agents: Embedded directly into RingCX workflows, native AI agents help with inbound and outbound interactions across voice and digital channels. For example, a business can run multi-step workflows from start to finish, such as confirm an appointment, handle verification, and update a record all within a single call. Autonomous Outreach: Leverage AI agents to proactively initiate conversation outreach triggered by real-time events: appointment reminders, payment notifications, service updates. For example, a credit card payment is missed. AIR Pro calls the customer, confirms the outstanding balance, offers payment options, and processes the payment over the phone. Intelligent Handoffs: When a conversation requires human judgment or empathy, AI agents in RingCX can transfer seamlessly to live agents, carrying full customer history and CRM data so the conversation continues without interruption, repetition, or lost context. AI-powered Workflow Builder: A natural language interface for building RingCX workflows on-demand, customers are able to prompt commands through RingCX’s AI Virtual Assistant (AVA) describing what they need, and it creates a workflow automatically — no coding, no technical resources required. AI-powered RingCX Analytics: Enables business and contact center leaders to prompt questions through RingCentral’s AI Virtual Assistant (AVA) within the RingCX interface to retrieve answers and specific metrics. For example, a newly hired supervisor can ask, "What report should I use to see an agent’s attendance and performance?" and AVA surfaces the answer instantly. New WEM Capabilities
RingCentral’s native WEM solution, called RingWEM, brings together AI Quality Management, AI Interaction Analytics, and AI Workforce Management embedded directly into RingCX – helping businesses reduce average call handle times, and improve customer satisfaction without a fragmented toolset that has long held back contact center performance. New RingWEM capabilities include:
RingWEM with Live Screen Monitoring: This gives supervisors visibility into how agents handle customer interactions, with the ability to whisper, coach, or step in without disrupting the customer experience. For example, it gives supervisors visibility during the call, seeing the agent’s screen in real time, and watching how agents address a problem, while giving coaching suggestions when the conversation is still live. Added Digital Channels
RingCX supports more than 20 digital channels, along with inbound and outbound voice allowing agents to manage various customer interactions from a single, unified interface. RingCX goes beyond the standard support for WhatsApp Messaging, and now includes WhatsApp Voice support.
WhatsApp Voice Support: With WhatsApp Voice in RingCX, customers can move from a messaging conversation to voice without leaving WhatsApp. The agent picks up the call with a complete view of the customer journey, including a summary of each interaction. “As a RingCX and AIR Pro customer, we're expanding our use of AI to drive a consistent customer experience while also enabling more automated AI and human interactions,” said Jaimie Bell, VP of Client Solutions at Office Gurus. “The expansion of AI Agents in RingCX, powered by AIR Pro, is really exciting. We're looking forward to it giving us more control and visibility into deploying AI agents at scale without sacrificing the quality our customers expect. We're early in implementation, and already seeing how AI agents will help us move faster, reduce manual overhead, and deliver a more seamless customer experience.”
RingCX Momentum
As of the end of Q1 2026, more than 1,700 businesses have adopted RingCX, up over 70% year-over-year – with more than half of them utilizing AI.
RingCX customers are achieving measurable results across industries. For example, in healthcare, Sun River Health achieved a 95% first-call resolution rate — 25% above industry standard. In entertainment, The Escape Game reduced costs by 50% while increasing bookings by 7%, and the San Diego Symphony cut box office hold times by 95%.
“The industry is moving beyond AI assistants towards increasingly autonomous AI agents that can participate in customer journeys alongside human workers,” said Hayley Sutherland, Conversational AI Analyst at IDC. “Organizations will need a common framework for managing performance, quality, analytics, and governance across both — and having that native to the contact center platform is the right approach. RingCentral's direction reflects its commitment to both supporting its customers with the capabilities needed today, and taking them where the market is headed.”
Pricing & Availability
Native AI Agents in RingCX and Automated Outreach will be available on a consumption basis, aligned with AIR Pro pricing. RingWEM with Live Screen Monitoring — will be priced on a seat basis or included in the RingCX Ultimate tier. New RingCX capabilities are currently in beta with general availability in 2H 2026. AI-powered RingCX Analytics and RingWEM with Live Screen Monitoring will be available in Q3.
For additional details or demo requests, visit the RingCentral booth #411 at CCW Las Vegas, or click here.
Join the RingCentral “CCW Special Edition” of AI Real Talk—Live or on-demand Elevate Every Customer Experience: Keeping Humans in the Loop While Scaling AI June 23 | 10:00 AM PT / 1:00 PM ET
About RingCentral
RingCentral is a global leader in AI–powered customer engagement, delivering an integrated platform for business phone, SMS, contact center, workforce engagement management, video collaboration, and messaging. Powered by advanced AI capabilities, RingCentral delivers intelligence at every phase of the conversation journey — before, during, and after each human interaction. With RingCentral, businesses can work smarter, respond faster, and connect more meaningfully with their customers. Visit ringcentral.com to learn more.
Joby Aviation is upgraded to Speculative Buy, reflecting reduced cash burn, strengthened balance sheet, and tangible commercialization milestones. JOBY's cash position rose to $2.47B with quarterly burn declining, extending its operational runway even before core revenue generation. Consecutive revenue beats, primarily from Blade acquisition, de-risk JOBY as it advances toward U.S. eVTOL commercialization and international expansion.
Industrial might is back in vogue, and not just for space-industry stocks. A new form of transportation is soon to make its debut in cities around the globe: electric vertical takeoff and landing (eVTOL) vehicles. Joby Aviation (JOBY 3.04%) is one of the publicly traded companies that manufactures these innovative aircraft, and it believes that it can transform transportation across cities.
Its product is neither an airplane nor a helicopter, but something in between, and fully electric-powered. With its stock price currently at just $9 per share, could getting in early on eVTOL pioneer Joby Aviation help make you rich? Let's take a closer look and find out.
Today's Change
(
-3.04
%) $
-0.29
Current Price
$
9.26
The future of short-haul flights The idea for eVTOLs came from two sources: the plague of car traffic in most large cities, and noise pollution from helicopters, which prevents them from operating in many areas. An eVTOL can operate quietly compared to a helicopter, transporting small groups of passengers from point to point using "vertiports" across metro areas.
Joby's aircraft is currently in the middle of certification with the Federal Aviation Administration (FAA), which requires rigorous testing for all eVTOL start-ups due to the novel nature of the vehicles. Joby began testing in 2018 and is reportedly close to the finish line, aiming to secure full regulatory approval in both the United States and Dubai within the next 12 months.
The company currently generates just a sliver of revenue from its Blade business, which is a helicopter and private-flight rideshare network focused on New York City. In the future, Joby plans to operate its own eVTOL ride-sharing for customers. Instead of just selling commercial aircraft to operators like Boeing, Joby wants to keep its aircraft and sell tickets directly to users through its own vertiport network. It will do so with partners like Delta Air Lines, connecting people at the airport to the potential of eVTOL services, a prime customer use case.
Image source: Getty Images.
Manufacturing progress and cash burn To get ahead of anticipated FAA approval, Joby has begun increasing its manufacturing capacity. It is currently producing two eVTOLs a month, for a rate of 24 per year. In the near future, it wants to double this manufacturing pace, and eventually produce 500 vehicles per year. With hundreds of cities around the world that could utilize eVTOL taxi networks, there is theoretical demand for this level of output from Joby and other eVTOL manufacturers racing for FAA approval.
Up-front spending will be massive. Joby needs to build aircraft and secure leases for vertiports before selling tickets to customers, which is why free cash flow has worsened over the past few years, hitting a record burn of $660 million over the last 12 months. At the end of the first quarter, the company had $2.5 billion in cash and equivalents, which gives it a few years of breathing room, but it's still not on a firm financial footing.
JOBY Revenue (TTM) data by YCharts.
Can Joby stock deliver life-changing returns? Joby Aviation is a high-risk stock. Let's say the company can eventually manufacture hundreds of aircraft a year, operate many air taxi networks in cities across the United States and globally, and improve traffic levels. If so, it's likely to get hundreds of millions (if not billions) of dollars in annual ticket revenue from customers who will pay a pretty penny to fly over traffic to places like the nearest airport.
The problem is that, despite a low per-share price of $9, Joby Aviation's market value is still quite high for a company that is close to a pre-revenue start-up. It currently has a market cap of $9.2 billion, pricing in a lot of this theoretical success before any FAA approval has been made. That should make you think twice about whether the stock can deliver life-changing returns for your portfolio.
Joby Aviation (NYSE:JOBY | JOBY Price Prediction) is graduating from a flight-test story to a revenue story. The Blade acquisition pushed Q4 2025 revenue to $30.84 million, management is guiding $105 million to $115 million for full-year 2026, and a JFK-to-Manhattan eVTOL flight put the brand in front of every commuter in the country.
Yet shares sit at $10, down 24.24% year to date. Can JOBY trade at $20 by 2028?
What’s Holding Joby Back Shares are stuck because of what investors are paying for unprofitable growth. Joby trades at a price-to-sales ratio of 122x with a beta of 2.67, punished whenever rate expectations shift. Shares are flat over the last month at 0%, with a recent 20% drop in June tied to a strong jobs report and renewed Fed tightening concerns.
Insider selling has weighed on sentiment. Director Paul Sciarra sold 416,666 shares at $12.02, and CFO Rodrigo Brumana followed with a $897,000 sale via a 10b5-1 plan. Both were pre-scheduled, but the optics hurt a stock already 47% below its 52-week high.
Wall Street Sees 11% Upside. Our Model Says 16%. Consensus target is $11.12, with 1 strong buy, 2 buys, 5 holds, 2 sells, and 1 strong sell. Our base-case model lands at $11.62 for a 16.2% upside, with a moderate 0.5 confidence score mirroring the analyst split of 27% bullish, 27% bearish, 45% neutral.
Consensus is too anchored on Joby being pre-revenue. The bull case points to $15.05 within twelve months and $25.75 over five years. Wall Street has not repriced for FAA certification, and that is the asymmetry worth watching.
The Path to $20 Per Share Reaching $20 from $10 requires a gain of 100%. With forward EPS of -$1.20, a price of $20 implies a forward P/E of -17x. The negative figure shows why our model excludes EPS and leans on analyst target weighting and the 247Factor of 1.045. For JOBY, price-to-sales is where the bull case has room.
If Joby hits a credible 2028 revenue ramp toward the $458 million projection being modeled post-FAA approval, the current 122x sales multiple compresses sharply at $20.
Three catalysts are in motion: the first point-to-point electric air taxi flight from JFK to Manhattan, selection for commercial operations in 11 states, and a Dubai launch with vertiports at the airport, Palm Jumeirah, and Dubai Mall.
CEO JoeBen Bevirt told investors, “2026 will mark a key inflection point for Joby”, and ARK Invest backed that view with a 119,000-share purchase after the FAA milestone. The primary risk is simple: any FAA Type Certification slip beyond 2026 resets the bull thesis.
Is $20 Realistic? Joby has no earnings power yet, which is the entire problem and opportunity. The stock sits at $10, against a 52-week range of $7.75 to $20.95, and a 50-day moving average of $9.79. Five-year total return is essentially flat at 0.4%.
The market has paid Joby for the option rather than the operating business. If Dubai service launches and the Dayton plant ramps to 4 aircraft per month in 2027, the option converts into cash flow.
Hitting $20 by 2028 requires a 100% gain, and on a beta of 2.67 that is achievable.
Three things must go right: FAA Type Certification by 2026, passenger revenue from Dubai and U.S. eIPP sites in 2027, and Dayton production hitting 4 aircraft per month on schedule. A certification delay forcing another dilutive capital raise derails it.
I view $20 as a stretch target with real catalysts behind it. Returns at this level shouldn’t be expected every year, but the blueprint for Joby reaching $20 in 2028 is clear.
Despite making headway on its regulatory path, Joby Aviation (JOBY 3.04%) has spent much of 2026 flying into strong headwinds. Indeed, shares of the electric vertical takeoff and landing (eVTOL) stock have fallen about 30% on the year and trade far below their 52-week high of about $21.
What gives? Wall Street's patience, I suppose. Joby has not fundamentally changed in the last year. In fact, its prospects have only gotten better: The company has never been closer to achieving FAA certification, and it just successfully piloted an eVTOL in and around New York City.
If Joby stays on its current path, this 30% dip could, in retrospect, represent an attractive buying window. Let's take a look.
Today's Change
(
-3.04
%) $
-0.29
Current Price
$
9.26
Joby is the front-runner of the nascent eVTOL industry Imagine a large drone you and a few friends can ride in; it takes off straight up from the ground, flies across the city over traffic and congested streets, then lands near an airport or your office. That, in a nutshell, is the kind of air taxi service Joby Aviation is trying to create.
And it's not alone. Early on, Toyota became its manufacturing mentor and an early investor. Joby has also partnered with Delta Air Lines and Uber, and it made a strategic acquisition of Blade Air Mobility.
Image source: Joby Aviation.
Each of these partnerships can accelerate the rate at which it brings its air taxis to the market. So can the eIPP (eVTOL Integration Pilot Program), a White House-backed initiative to begin testing eVTOL operations in select cities ahead of FAA type certification. The program, slated to begin in the second half of this year, gives Joby a chance to build experience before commercialization begins.
Joby is currently in Stage 4 of the FAA's five-stage type certification process, and it began for-credit flight testing in March 2026. At this point, the FAA is scrutinizing Joby's aircraft to determine whether it meets requirements, rather than just reviewing a design on paper.
Nobody knows when this process will finish -- it could drag on for months -- but if this were a race among eVTOL companies, Joby would be in the lead. The closest competitor, Archer Aviation, recently began its own for-credit flight testing. Both companies are expected to start generating more substantial revenue within the next two years, as shown in the chart.
Data by YCharts
In 2021, Morgan Stanley published a report on eVTOLs and urban air mobility. In that report, it predicted, in the most bullish scenario, that the industry would grow to $1 trillion by 2040 and $9 trillion by 2050. As the researchers put it, "Our key message to investors: Temper your excitement with patience. The market opportunity for eVTOL/UAM could be far bigger than you think, but we believe it may require decades to reach high-volume commercialization.
Those interested in Joby today should approach the stock with the long-term perspective of decades, not years. For investors willing to wait that long, today's share price may ultimately matter far less than whether Joby turns a radical idea into a new mode of transportation.
United Parks and Resorts is rated "BUY," supported by improving forward indicators and trading at a 10.7x forward P/E, below its historical peak. Despite a weak 1Q26 due to adverse weather and lower international visitors, PRKS grew in-park per capita spending by 5.3% year-over-year. Management guides for accelerated revenue and EBITDA growth in 2H26, driven by new attractions and a rebound in international tourism.
Archer Aviation (ACHR 2.67%) and Kraken Robotics are two companies operating at the forefront of new technologies. Archer is a leader in electric vertical take-off and landing (eVTOL) aircraft, and Kraken is a leader in subsea batteries, ocean-floor mapping technologies, Lidar, and mine detection. Both companies have substantial growth opportunities in the defense sector.
Military budgets are rising around the world, and countries are taking steps to ensure that they are sufficiently positioned when it comes to next-gen defense technologies. With that in mind, is Archer Aviation or Kraken Robotics the better defense stock buy?
Image source: Getty Images.
Archer Aviation and Kraken Robotics at a glance Archer Aviation's business didn't post any sales last year, but the company did record revenue of $1.6 million in this year's first quarter and expects to begin commercial flight operations this year. The company currently has a market capitalization of roughly $4.2 billion.
Today's Change
(
-2.67
%) $
-0.14
Current Price
$
5.11
In addition to defense applications, Archer is also positioning commercial flights as a central component of its growth story. The company expects to begin commercial flights of its Midnight eVTOL aircraft in the United Arab Emirates this year, and it's moving through the certification process to secure the approval to fly in U.S. skies and other markets.
Meanwhile, Kraken recorded sales of roughly 102 million Canadian dollars (about $72 million USD based on the current exchange rate) in 2025. Kraken recorded net income of CA$2.9 million (roughly $2.1 million) last year, and Archer Aviation posted a net loss of $618.2 million.
Today's Change
(
-1.38
%) $
-0.07
Current Price
$
4.95
The scope of Kraken's business is also poised to expand dramatically thanks to the company's acquisition of Covelya -- another leader in the maritime technologies space. Kraken currently has a market cap of roughly $1.7 billion, but that figure will likely rise closer to $2 billion when the company issues new stock to complete its acquisition of Covelya.
Notably, both Archer and Kraken have partnerships with Anduril -- one of the most exciting companies when it comes to next-generation defense tech. Archer has teamed with Anduril to develop hybrid VTOL aircraft for military applications. Meanwhile, Kraken's batteries and sensor technologies are used in Anduril's GhostShark, Dive-LD, and Dive-XL unmanned, underwater drones. Covelya's Sonardyne technologies are also used in Anduril's sea drones, and the combination with Kraken should open up cross-selling opportunities across their respective customer bases and open the door for new selling and administrative efficiencies.
Which stock is the better buy? Between the two companies, I think Kraken stands out as the better buy right now. Despite having a significantly lower market capitalization, Kraken's commercialization ramp is significantly further along -- while also still offering big long-term growth potential. With Anduril seemingly set to ramp up production of its underwater drone platforms in the coming years, Kraken has some powerful performance catalysts on the horizon.
The company is also posting gross margins that look quite encouraging for a heavily hardware-focused business. The subsea tech specialist recorded a gross margin of 62.1% last year, and it's guiding for a gross margin between 55% and 60% this year.
Archer Aviation's business could scale rapidly, but I see a longer and tougher path to profitability and strong earnings growth. With that in mind, I think that Kraken stands out as a better buy for investors seeking next-gen defense plays.
Key Takeaways ACHR plans to use Hawthorne Airport as the operational hub for its Los Angeles air taxi network.The site will support takeoff, landing, maintenance, passenger handling and ground operations.ACHR is planning up to 200,000 sq. ft. of hangar space for air mobility and innovation activities. Archer Aviation Inc. (ACHR - Free Report) is giving its air taxi strategy a stronger operating base through its control of Hawthorne Airport near Los Angeles International Airport and Downtown Los Angeles. The company plans to use the site as the operational hub for its Los Angeles network while also developing it as an innovation center for next-generation AI-powered aviation technologies. This makes the airport more than a real estate asset. It can become a testing and coordination point for the company’s broader urban air mobility ambitions.
The move is important because commercial air taxi service will require more than certified aircraft. Archer Aviation will also need take-off and landing access, hangar capacity, maintenance support, passenger handling systems, ground operations and local regulatory coordination. Hawthorne Airport gives the company a place to bring many of these requirements together in one market that could be important for early adoption.
Archer Aviation also expects to prepare the site for planned air taxi operations in the Los Angeles area and potential use around the LA28 Olympic Games. The company has discussed the redevelopment of up to 200,000 square feet of hangar space and the creation of an advanced air mobility center of excellence. Over time, Archer Aviation aims to add AI-supported features such as air traffic coordination, ground operations management, maintenance detection and smoother passenger screening.
The company noted that capital projects at Hawthorne may face cost, permitting, labor, regulatory and schedule risks. If Archer Aviation can manage these challenges, Hawthorne Airport could support its shift from aircraft development toward real-world air taxi operations.
Companies Expanding Air Mobility NetworksAs companies move closer to commercial air mobility services, building operational networks is becoming increasingly important. Companies like Joby Aviation, Inc. (JOBY - Free Report) and Eve Holding, Inc. (EVEX - Free Report) are also expanding networks to support future air mobility operations.
Joby Aviation is developing flight networks and operational capabilities to support the planned rollout of its electric air taxi services.
Eve Holding is working with partners and stakeholders to help establish the network needed for future urban air mobility operations.
Earnings Estimates for ACHR StockThe Zacks Consensus Estimate for 2026 and 2027 earnings per share suggests a year-over-year decline of 61.90% and growth of 7.51%, respectively.
Image Source: Zacks Investment Research
ACHR Stock Trading at a DiscountArcher Aviation is trading at a discount relative to the industry, with a trailing 12-month price-to-book of 1.98X compared with the industry average of 6.03X
Image Source: Zacks Investment Research
ACHR Stock Price PerformanceOver the past three months, ACHR shares have fallen 1.5% compared with the industry’s 0.2% decline.
Image Source: Zacks Investment Research
ACHR’s Zacks RankArcher Aviation currently has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
ACHR advances VTOL testing and regulatory milestones, with the upcoming eIPP participation and Restricted Type Certificate program supporting intermediate-term US/UAE commercialization. With a growing order book nearing $6B as of 2024 and an expanded manufacturing cadence, the VTOL company appears well on track to rapidly monetize their offerings upon FAA certification. These tailwinds are, albeit, negated by ACHR's elevated cash burn rate as they intensify their multi-pronged testing/manufacturing/training/operations at Hawthorne Airport in LA/commercialization cadence.
Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of PennyMac Financial Services, Inc. (NYSE: PFSI) resulting from allegations that PennyMac may have issued materially misleading business information to the investing public.
So What: If you purchased PennyMac securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.
What to do next: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=51887 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
What is this about: On January 29, 2026, PennyMac filed a Current Report with the Securities Exchange Commission on Form 8-K announcing PennyMac's fourth quarter and full-year 2025 financial results. The report stated that PennyMac's "servicing segment pretax income was $37.3 million, down from $157.4 million in the prior quarter and $87.3 million in the fourth quarter of 2024," as well as "[retax income excluding valuation-related items was $47.8 million, down 70 percent from the prior quarter driven primarily by increased realization of mortgage servicing rights (MSR) cash flows as lower mortgage rates drove higher prepayment activity."
On this news, PennyMac's stock price fell $49.78 per share, or 33.3%, to close at $99.92 per share on January 30, 2026.
Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com
WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of PennyMac Financial Services, Inc. (NYSE: PFSI) resulting from allegations that PennyMac may have issued materially misleading business information to the investing public.
SO WHAT: If you purchased PennyMac securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.
WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=51887 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
WHAT IS THIS ABOUT: On January 29, 2026, PennyMac filed a Current Report with the Securities and Exchange Commission on Form 8-K announcing PennyMac’s fourth quarter and full-year 2025 financial results. The report stated that PennyMac’s “servicing segment pretax income was $37.3 million, down from $157.4 million in the prior quarter and $87.3 million in the fourth quarter of 2024,” as well as “[retax income excluding valuation-related items was $47.8 million, down 70 percent from the prior quarter driven primarily by increased realization of mortgage servicing rights (MSR) cash flows as lower mortgage rates drove higher prepayment activity.”
On this news, PennyMac’s stock price fell $49.78 per share, or 33.3%, to close at $99.92 per share on January 30, 2026.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827 [email protected]
www.rosenlegal.com
NEW YORK, June 24, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into PennyMac Financial Services, Inc. (NYSE:PFSI) for potential violations of the federal securities laws.
If you invested in PennyMac, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/pennymac-class-action-lawsuit.
Why is PennyMac Being Investigated for Violations of the Federal Securities Laws?
PennyMac originates and services home mortgages. Recently, PennyMac increased its capacity to originate loans to better retain borrowers seeking to refinance their mortgages—a process known as “recapture” —as interest rates declined. During the relevant period, PennyMac touted the success of its recapture efforts, representing to investors that its recapture rates were improving.
BFA is investigating whether PennyMac misrepresented its ability to recapture customers refinancing their mortgages as interest rates declined.
Why did PennyMac’s Stock Drop?
On January 29, 2026, PennyMac reported disappointing 4Q 2025 financial results. During PennyMac’s earnings call held the same day, PennyMac senior management revealed that although PennyMac had increased its origination capacity to recapture more refinance business, many competitors had also added capacity, creating a highly competitive origination environment that constrained PennyMac’s ability to take advantage of refinance opportunities. This news caused the price of PennyMac stock to decline more than 37%, from $140.70 per share at the close of trading on January 29, 2026, to as low as $93.50 per share on January 30, 2026.
Click here for more information: https://www.bfalaw.com/cases/pennymac-class-action-lawsuit.
What Can You Do?
If you invested in PennyMac, you may have legal options and are encouraged to submit your information to the firm.
All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters.
Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff’s securities litigation law firm, with clients noting: “[t]here is no better service provider in the practice area,” “[t]he interest of the client is always front and center,” and “[t]here isn’t a better firm in this space.” One testimonial described the firm as “nimble and entrepreneurial,” with a “relentless focus on adding value for clients.”
Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.
For more information about BFA and its attorneys, please visit https://www.bfalaw.com.
Attracting over 15.7 million MICE visits since 2007
Elevating Macao's international competitiveness through long-term
non-gaming investment
, /PRNewswire/ -- Since the opening of Sands® Macao in 2004, Sands China Ltd. has remained committed to contributing to Macao's development into a World Centre of Tourism and Leisure. As a trailblazer of Macao's integrated resort model, Sands China has placed hospitality, retail, entertainment, and MICE (meetings, incentives, conferences and exhibitions) at the core of its non-gaming development strategy. For over two decades, the company has continuously invested in both infrastructure and software to broaden the scope and depth of the city's industries, in support of the Macao SAR government's economic diversification direction.
Sands China has long played a proactive role in promoting Macao’s MICE industry, leveraging its world-class integrated resorts to enhance the city’s capacity and competitiveness in hosting large-scale international MICE events. As of now, Sands China has hosted nearly 12,800 MICE events, attracting over 15.7 million MICE visits from around the world. These efforts continue to strengthen Macao’s position as one of the premier MICE tourism destinations in Greater China, Asia, and globally. (The 2018 Macao International Environmental Co-operation Forum and Exhibition)
Sands China has long played a proactive role in promoting Macao’s MICE industry, leveraging its world-class integrated resorts to enhance the city’s capacity and competitiveness in hosting large-scale international MICE events. As of now, Sands China has hosted nearly 12,800 MICE events, attracting over 15.7 million MICE visits from around the world. These efforts continue to strengthen Macao’s position as one of the premier MICE tourism destinations in Greater China, Asia, and globally. (The 13th Macao International Travel (Industry) Expo, 2025)
Sands China has long played a proactive role in promoting Macao’s MICE industry, leveraging its world-class integrated resorts to enhance the city’s capacity and competitiveness in hosting large-scale international MICE events. As of now, Sands China has hosted nearly 12,800 MICE events, attracting over 15.7 million MICE visits from around the world. These efforts continue to strengthen Macao’s position as one of the premier MICE tourism destinations in Greater China, Asia, and globally. (The 14th Macao International Travel (Industry) Expo, 2026)
Sands China has long played a proactive role in promoting Macao’s MICE industry, leveraging its world-class integrated resorts to enhance the city’s capacity and competitiveness in hosting large-scale international MICE events. As of now, Sands China has hosted nearly 12,800 MICE events, attracting over 15.7 million MICE visits from around the world. These efforts continue to strengthen Macao’s position as one of the premier MICE tourism destinations in Greater China, Asia, and globally. (The 14th Macao International Travel (Industry) Expo, 2026)
Sands China has long played a proactive role in promoting Macao’s MICE industry, leveraging its world-class integrated resorts to enhance the city’s capacity and competitiveness in hosting large-scale international MICE events. As of now, Sands China has hosted nearly 12,800 MICE events, attracting over 15.7 million MICE visits from around the world. These efforts continue to strengthen Macao’s position as one of the premier MICE tourism destinations in Greater China, Asia, and globally. (Global Gaming Expo Asia 2026) With the opening of The Venetian® Macao in 2007, Sands China took a forward-looking approach by establishing Cotai Expo, the largest MICE facility in Macao — laying a solid foundation for the city's international competitiveness in the MICE industry. Over the years, the company has been steadfast in advancing non-gaming development, driving Macao's MICE sector to evolve from an emerging industry into a high-growth pillar. Sands China successfully developed and enriched the integrated model that enables multiple experiences within a single stop. To date, the company's total MICE facilities span over 1.6 million square feet, continuing to scale the international and professional development of the sector.
Under strong policy support from both the central and Macao SAR governments, Macao's MICE industry has expanded significantly, becoming one of the key engines driving progress in the city's diversification. Sands China has long played a proactive role in promoting the industry's advancement. It has leveraged its world-class integrated resorts to enhance Macao's capacity and competitiveness in hosting large-scale international MICE events, successfully attracting a wide range of globally influential, high-value conferences and exhibitions to the city.
As of now, Sands China has hosted nearly 12,800 MICE events across a broad spectrum of global industries, attracting over 15.7 million MICE visits from around the world. These efforts continue to strengthen Macao's position as one of the premier MICE tourism destinations in Greater China, Asia, and globally.
Sands China firmly believes that MICE serves as a powerful economic multiplier, conducive to fostering the development of related industries. Its strong international connectivity also enables the city to attract a broad base of global business travellers and professionals, further expanding Macao's international source markets. Sands China has long tapped into the continued hosting of high-quality international MICE events as part the company's approach to elevate Macao's appeal to global tourists. In 2025 alone, Sands China recorded 380,000 room nights by international guests across its integrated resorts.
Grant Chum, chief executive officer and executive director of Sands China Ltd., said: "Over the years, Sands China has played a pivotal role in developing Macao's MICE industry, integrating MICE deeply within our integrated resort model. We have built large-scale, high-quality MICE infrastructure in Macao, continuously elevating the sector into a strategic drawcard and tourism product that connects Macao with global markets, strengthens the city's international competitiveness, and supports its broader economic diversification. Since 2007, Sands China has attracted over 15.7 million MICE visits. As the local MICE industry continues to flourish, Macao has increasingly established itself as one of the world's most influential business and tourism destinations, underscoring the sector's contribution to the city's diversified economic growth.
"Looking ahead, Sands China will continue to align closely with the Macao SAR government's 'Tourism+' policy. Through the continued strengthening of synergies across non-gaming sectors, our company endeavours to further elevate Macao's global competitiveness and appeal, while supporting the development of its diversified economy, and remains committed to consolidating the city's position as a World Centre of Tourism and Leisure."
Sands China holds unwavering confidence in Macao's long term development trajectory. As the company continues to strengthen its business performance, it maintains its commitment to long-term investment in the city. The company is proactively deepening high-quality, non-gaming "Tourism+" initiatives to support Macao's overall development strategy –– striving to further enrich Macao's appeal as a City of Events and contribute to its long-term, sustainable and diversified growth.
About Sands China Ltd.
Sands China Ltd. (Sands China or the Company) is incorporated in the Cayman Islands with limited liability and is listed on The Stock Exchange of Hong Kong Limited (HKEx: 1928). Sands China is the largest operator of integrated resorts in Macao. The Company's integrated resorts on the Cotai Strip comprise The Venetian® Macao, The Plaza® Macao, The Parisian® Macao and The Londoner® Macao. The Company also owns and operates Sands® Macao on the Macao peninsula. The Company's portfolio features a diversified mix of leisure and business attractions and transportation operations, including large meeting and convention facilities; a wide range of restaurants; shopping malls; world-class entertainment at The Venetian Arena, The Londoner Arena, The Venetian Theatre, The Parisian Theatre, The Londoner Theatre and Sands Theatre; and a high-speed Cotai Water Jet ferry service between Hong Kong and Macao. The Company's Cotai Strip portfolio has the goal of contributing to Macao's transformation into a world centre of tourism and leisure. Sands China is a subsidiary of global resort developer Las Vegas Sands Corp. (NYSE: LVS).
For more information, please visit www.sandschina.com.
Media contacts:
Corporate Communications, Sands China Ltd.
Mabel Wu
Tel: +853 8118 2268
Email: [email protected]
Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.
While many investors like to look for momentum in stocks, this can be very tough to define. There is a lot of debate surrounding which metrics are the best to focus on and which are poor quality indicators of future performance. The Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us.
Below, we take a look at Arrow Electronics (ARW - Free Report) , a company that currently holds a Momentum Style Score of B. We also talk about price change and earnings estimate revisions, two of the main aspects of the Momentum Style Score.
It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. Arrow Electronics currently has a Zacks Rank of #1 (Strong Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of "A or B" outperform the market over the following one-month period.
You can see the current list of Zacks #1 Rank Stocks here >>>
Set to Beat the Market? In order to see if ARW is a promising momentum pick, let's examine some Momentum Style elements to see if this electronics maker holds up.
A good momentum benchmark for a stock is to look at its short-term price activity, as this can reflect both current interest and if buyers or sellers currently have the upper hand. It is also useful to compare a security to its industry, as this can help investors pinpoint the top companies in a particular area.
For ARW, shares are up 2.61% over the past week while the Zacks Electronics - Parts Distribution industry is up 2.61% over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 7.07% compares favorably with the industry's 5.98% performance as well.
While any stock can see a spike in price, it takes a real winner to consistently outperform the market. Shares of Arrow Electronics have increased 66.65% over the past quarter, and have gained 88.13% in the last year. On the other hand, the S&P 500 has only moved 13.8% and 26.67%, respectively.
Investors should also pay attention to ARW's average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. ARW is currently averaging 581,848 shares for the last 20 days.
Earnings OutlookThe Zacks Momentum Style Score also takes into account trends in estimate revisions, in addition to price changes. Please note that estimate revision trends remain at the core of Zacks Rank as well. A nice path here can help show promise, and we have recently been seeing that with ARW.
Over the past two months, 4 earnings estimates moved higher compared to none lower for the full year. These revisions helped boost ARW's consensus estimate, increasing from $13.59 to $19.15 in the past 60 days. Looking at the next fiscal year, 4 estimates have moved upwards while there have been no downward revisions in the same time period.
Bottom LineTaking into account all of these elements, it should come as no surprise that ARW is a #1 (Strong Buy) stock with a Momentum Score of B. If you've been searching for a fresh pick that's set to rise in the near-term, make sure to keep Arrow Electronics on your short list.
This transaction strengthens Organon’s contraception portfolio and expands long-acting reversible options for women
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, today announced the completion of a global licensing agreement with Sebela Pharmaceuticals, granting Organon exclusive rights to MIUDELLA®, a hormone-free, copper intrauterine device (IUD). Please see our prior announcement for a summary of the transaction terms.
Approved by the US Food and Drug Administration (FDA) on February 24, 2025, MIUDELLA is the first hormone-free copper IUD to be introduced in the US in over 40 years. Indicated for the prevention of pregnancy for up to three years in females of reproductive potential, MIUDELLA is 99% effective. It features a proprietary SLIMSERTTM technology, which consists of a highly flexible frame and a fully preloaded inserter with a small, tapered insertion tube diameter of 3.7mm.1
MIUDELLA is anticipated to be commercially available in late 2026. The MIUDELLA label includes a Risk Evaluation and Mitigation Strategy (REMS). A REMS is a strategy used by the FDA to manage known or potential risks associated with a product. To mitigate complications due to potential improper insertion, MIUDELLA will only be available in the US through the MIUDELLA REMS program. See additional safety information below.
“MIUDELLA represents an important hormone-free option in contraception, expanding choices for women seeking long‑acting reversible birth control,” said Joe Morrissey, Chief Executive Officer of Organon. “By building on our long history in contraception and leveraging our deep expertise and capabilities, this agreement strengthens Organon’s ability to deliver contraceptive options that meet the needs of women.”
“Developed by Sebela Women’s Health, MIUDELLA represents an effective option for pregnancy prevention,” said Alan Cooke, Chief Executive Officer and President of Sebela Pharmaceuticals. “We are delighted to complete this global license agreement with Organon. Organon offers the scale, launch readiness and access capabilities needed to bring this valuable product efficiently into clinical practice and help ensure MIUDELLA reaches more women who are looking for hormone-free contraception options.”
Truist Securities, Inc. acted as financial advisor to Sebela Pharmaceuticals.
About MIUDELLA
MIUDELLA was investigated in three clinical trials in the US in 1,904 women aged 17 to 45 years. The Phase 3 prospective, multicenter, single-arm, open-label study was conducted in 42 centers in the US with a primary endpoint of contraceptive efficacy through 3 years of use as assessed by the Pearl Index (defined as the number of pregnancies per 100 women over one year).1 In the efficacy cohort of women aged 17 to 35 years from the Phase 3 study (n=1397), the first-year Pearl Index was 0.94 (95% CI, 0.43-1.78) and the cumulative 3-year Pearl Index was 1.05 (95% CI, 0.66-1.60)—in other words, 99% effective, with an overall placement success rate of 98.8%. The most common adverse reactions (≥5%) observed in clinical trials were heavy menstrual bleeding, dysmenorrhea, intermenstrual bleeding, pelvic discomfort, procedural pain, pelvic pain, post-procedural hemorrhage, and dyspareunia. In the first year, 8.5% of participants across all three studies discontinued treatment due to bleeding or pain adverse events, which decreased to 3.2% by year 3. Expulsion rates ranged from 1.9% in year 1 to 0.9% in year 3.
Indication
MIUDELLA® is a copper-containing intrauterine system (IUS) indicated for prevention of pregnancy in females of reproductive potential for up to 3 years. Selected Safety Information
WARNING: RISK OF COMPLICATIONS DUE TO IMPROPER INSERTION
Improper insertion of intrauterine systems, including MIUDELLA, increases the risk of complications. Proper training prior to first use of MIUDELLA can minimize the risk of improper insertion. MIUDELLA is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the MIUDELLA REMS program to ensure all healthcare providers are trained on the proper insertion of MIUDELLA prior to first use. Further information is available at miudellarems.com and 1-855-337-0772. CONTRAINDICATIONS
Use of MIUDELLA is contraindicated when 1 or more of the following conditions exist: Pregnancy or suspicion of pregnancy; congenital or acquired abnormalities of the uterus, including leiomyomas, resulting in distortion of the uterine cavity; acute pelvic inflammatory disease (PID); postpartum endometritis or postabortal endometritis in the past 3 months; known or suspected uterine or cervical malignancy; for use as postcoital contraception (emergency contraception); uterine bleeding of unknown etiology; untreated acute cervicitis or vaginitis or other lower genital tract infection; conditions associated with increased susceptibility to pelvic infections; Wilson's disease; a previously placed IUS that has not been removed; hypersensitivity to any component of MIUDELLA including to polypropylene, copper, nitinol, an alloy of nickel and titanium, or any of the trace elements present in the copper component of MIUDELLA. Persons with allergic reactions to these components may suffer an allergic reaction to this intrauterine system. Prior to placement, patients should be counseled on the materials contained in the IUS, as well as potential for allergy/hypersensitivity to these materials. WARNINGS AND PRECAUTIONS
Risk of Complications Due to Improper Insertion: Improper insertion of IUSs, including MIUDELLA, increases the risk of perforation, infection, undiagnosed abnormal bleeding, pregnancy loss (if pregnancy occurs with IUS in situ), and expulsion. Proper training prior to first use of MIUDELLA can minimize the risk of improper insertion. MIUDELLA is available only through a restricted program under a REMS. MIUDELLA REMS: MIUDELLA is only available through a restricted program under a REMS called MIUDELLA REMS Program to ensure healthcare providers are trained prior to first use. Notable requirements include the following: Healthcare providers must be certified with the program by enrolling and completing training on the proper insertion of MIUDELLA prior to first use. Pharmacies and healthcare settings that dispense MIUDELLA must be certified by enrolling in the REMS and must only dispense MIUDELLA to certified healthcare providers. Further information is available at www.miudellarems.com and 1-855-337-0772.
Ectopic Pregnancy: Promptly evaluate females who become pregnant for ectopic pregnancy while using MIUDELLA. Ectopic pregnancy may require surgery and may result in loss of fertility. Intrauterine Pregnancy: Increased risk of spontaneous abortion, septic abortion, premature delivery, sepsis, septic shock, and death if pregnancy occurs. Remove MIUDELLA if pregnancy occurs with MIUDELLA in place and the thread ends are visible or can be retrieved from the cervical canal. Sepsis: Severe infection or sepsis, including Group A streptococcal sepsis (GAS), have been reported following insertion of other IUSs; strict aseptic technique is essential during insertion. Pelvic Infection: Promptly examine users with complaints of lower abdominal or pelvic pain, odorous discharge, unexplained bleeding, fever, genital lesions or sores after insertion of MIUDELLA. IUSs have been associated with an increased risk of PID, most likely due to organisms being introduced into the uterus during insertion. Remove MIUDELLA in cases of recurrent PID or endometritis, or if an acute pelvic infection is severe or does not respond to treatment. Subclinical PID: PID may be asymptomatic but still result in tubal damage and its sequelae.
Perforation: Partial or total perforation of the uterine wall or cervix may occur during insertions, although the perforation may not be detected until sometime later. Perforation may also occur at any time during IUS use. Perforation that results in embedment or translocation may reduce contraceptive efficacy and result in pregnancy. Risk is increased if inserted in postpartum and lactating females and may be increased if inserted in females with fixed, retroverted uteri or noninvoluted uteri. If perforation is suspected or if known perforation occurs during placement, the IUS should be removed as soon as possible. Surgery may be required. Delayed detection or removal of MIUDELLA in cases of perforation may result in migration outside the uterine cavity, adhesions, peritonitis, intestinal penetration, intestinal obstruction, abscesses and/or damage to adjacent organs. Expulsion: Partial or complete expulsion of MIUDELLA has been reported, resulting in the loss of contraceptive protection. MIUDELLA should be placed no earlier than 4 weeks post-pregnancy to mitigate the risk of expulsion that may be increased when the uterus is not completely involuted at the time of insertion. Remove a partially expelled MIUDELLA and do not attempt to push a partially expelled MIUDELLA into the uterus. Wilson’s Disease: MIUDELLA may exacerbate Wilson’s disease, a rare genetic disease affecting copper excretion; therefore, the use of MIUDELLA is contraindicated in females with Wilson’s disease. Bleeding Pattern Alterations: Menstrual bleeding may be altered and result in heavier and longer bleeding with spotting. Females complaining of heavy vaginal bleeding should be evaluated and treated, and may need to discontinue MIUDELLA. Magnetic Resonance Imaging (MRI) Safety Information: Patients using MIUDELLA can be safely scanned with MRI only under certain conditions. Medical Diathermy: Medical equipment that contains high levels of Radiofrequency (RF) energy such as diathermy may cause health effects (by heating tissue) in females with a metal-containing IUS including MIUDELLA. Avoid using high medical RF transmitter devices in females with MIUDELLA. ADVERSE REACTIONS
Most common adverse reactions (≥5%) observed in clinical trials were heavy menstrual bleeding, dysmenorrhea, intermenstrual bleeding, pelvic discomfort, procedural pain, pelvic pain, post-procedural hemorrhage, and dyspareunia. Before prescribing MIUDELLA, please read the full Prescribing Information, including Boxed Warning.
About Organon
Organon (NYSE: OGN) is a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. With a portfolio of over 70 products across Women’s Health and General Medicines, which includes biosimilars, Organon focuses on addressing health needs that uniquely, disproportionately or differently affect women, while expanding access to essential treatments in over 140 markets.
Headquartered in Jersey City, New Jersey, Organon is committed to advancing access, affordability, and innovation in healthcare. Learn more at www.organon.com and follow us on LinkedIn, Instagram, X, YouTube, TikTok and Facebook.
Cautionary Note Regarding Forward-Looking Statements
Except for historical information, this press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about the potential benefits of Organon’s exclusive license of global rights to MIUDELLA® and expectations regarding the timing of commercialization thereof. Forward-looking statements may be identified by words such as “anticipated, “may”, “will”, and “expected,” among others. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate, or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include, but are not limited to, weakening of economic conditions that could adversely affect the level of demand for MIUDELLA®; pricing pressures globally, including rules and practices of managed care groups, judicial decisions and governmental laws and regulations related to or affecting Medicare, Medicaid and healthcare reform, pharmaceutical pricing and reimbursement, access to the company’s products, international reference pricing, including most-favored-nation drug pricing, and other pricing related initiatives and policy efforts; the impact of tariffs and other trade restrictions or domestic sourcing requirements; expanded brand and class competition in the markets in which the company operates; the failure of any supplier to provide substances, materials, or services as agreed, or otherwise meet their obligations to the company; the increased cost of supply, manufacturing, packaging, and operations; difficulties developing and sustaining relationships with commercial counterparties, including Sebela Pharmaceuticals; the impact of higher selling and promotional costs; efficacy, safety or other quality concerns with respect to the company’s marketed products, whether or not scientifically justified, leading to product recalls, withdrawals, labeling changes or declining sales; future actions of third parties, including significant changes in customer relationships or changes in the behavior and spending patterns of purchasers of healthcare products and services, including delaying medical procedures, rationing prescription medications, reducing the frequency of physician visits and forgoing healthcare insurance coverage; the failure by the company or its third party collaborators and/or their suppliers to fulfill their or their regulatory or quality obligations; and volatility of commodity prices, fuel, and shipping rates that impact the costs and/or ability to supply the company’s products. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s filings with the SEC, including the company’s most recent Annual Report on Form 10-K and subsequent SEC filings, available at the SEC’s Internet site (www.sec.gov). References and links to websites have been provided for convenience, and the information contained on any such website is not a part of, or incorporated by reference into, this press release. Organon is not responsible for the contents of third-party websites.
About Sebela Pharmaceuticals
At Sebela Pharmaceuticals, we are building a leading gastroenterology company in the US and developing innovative products in women’s health. Braintree Laboratories, Inc., a part of Sebela Pharmaceuticals, has been innovating, developing, manufacturing, and commercializing gastroenterology products for over 40 years. Tegoprazan is Braintree’s lead program in GERD, and in 2025 Sebela Women’s Health obtained FDA approval for Miudella (copper-containing intrauterine system), the first non‑hormonal intra‑uterine device (IUD) for contraception approved in over 40 years. Sebela Pharmaceuticals has operations in Roswell, GA; Braintree, MA; and Dublin, Ireland.
For more information, visit www.sebelapharma.com.
Sebela Forward-Looking Statement
This press release and any statements made for and during any presentation or meeting contain forward-looking statements related to Sebela Pharmaceuticals, Sebela Women’s Health and Braintree Laboratories under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. These statements may be identified by the use of forward-looking words such as "anticipate," "planned," "believe," “may”, “will”, "forecast," "estimated," "expected," and "intend," among others. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the development, launch, introduction and commercial potential of Miudella; growth and opportunity, including peak sales and the potential demand for Miudella, as well as its potential impact on applicable markets; market size; substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third-party payer reimbursement; dependence upon third parties; our financial performance and results, including the risk that we are unable to manage our operating expenses or cash use for operations, or are unable to commercialize our products, within the guided ranges or otherwise as expected; and risks related to noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development and commercialization of new products. There are no guarantees that Miudella will prove to be commercially successful. While the list of factors presented here is considered representative, no such list should be considered a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and neither Sebela Pharmaceuticals, Sebela Women’s Health nor Braintree Laboratories agree to undertake any obligation to update publicly such statements to reflect subsequent events or circumstances except as required by law.
Organon (OGN - Free Report) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.
Shares of this pharmaceutical company have returned 0% over the past month versus the Zacks S&P 500 composite's +2% change. The Zacks Medical Services industry, to which Organon belongs, has gained 3.6% over this period. Now the key question is: Where could the stock be headed in the near term?
While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.
Earnings Estimate RevisionsHere at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.
We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For the current quarter, Organon is expected to post earnings of $0.87 per share, indicating a change of -13% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days.
The consensus earnings estimate of $3.37 for the current fiscal year indicates a year-over-year change of -7.9%. This estimate has remained unchanged over the last 30 days.
For the next fiscal year, the consensus earnings estimate of $3.61 indicates a change of +7% from what Organon is expected to report a year ago. Over the past month, the estimate has remained unchanged.
With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Organon.
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Projected Revenue GrowthWhile earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.
For Organon, the consensus sales estimate for the current quarter of $1.54 billion indicates a year-over-year change of -3.3%. For the current and next fiscal years, $6.11 billion and $6.14 billion estimates indicate -1.6% and +0.4% changes, respectively.
Last Reported Results and Surprise HistoryOrganon reported revenues of $1.46 billion in the last reported quarter, representing a year-over-year change of -3.5%. EPS of $0.71 for the same period compares with $1.02 a year ago.
Compared to the Zacks Consensus Estimate of $1.47 billion, the reported revenues represent a surprise of -0.48%. The EPS surprise was -14.46%.
Over the last four quarters, Organon surpassed consensus EPS estimates two times. The company topped consensus revenue estimates two times over this period.
ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.
While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.
As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Organon is graded A on this front, indicating that it is trading at a discount to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Bottom LineThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Organon. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
The launch expands Organon’s biosimilars portfolio in Canada to eight products spanning five therapeutic areas
KIRKLAND, Quebec & SHANGHAI--(BUSINESS WIRE)--Organon Canada and Shanghai Henlius Biotech, Inc. (2696.HK) today announced that BILDYOS® (denosumab injection) 60 mg/1 mL and TUZEMTY® (denosumab injection) 120 mg/1.7 mL, biosimilars to PROLIA and XGEVA, respectively, are now available in Canada for all indications of reference products. Used across several indications, denosumab products treat osteoporosis and bone events associated with cancer by helping to strengthen bones.
“The approvals represent an important step toward helping broaden access to bone-care treatments in Canada. These biosimilars will introduce additional treatment options across several therapeutic areas, including osteoporosis, which predominantly affects women and impacts 2.3 million Canadians,”1 said Dominic Bégin, President and Managing Director at Organon Canada. “This development reinforces Organon’s commitment to expanding its biosimilar portfolio, improving treatment accessibility, and helping to strengthen the healthcare system while supporting patients in need.”
With this launch, Organon reinforces its commitment to offering patients in Canada more treatment options and helping to reduce healthcare costs by increasing access to biosimilars. BILDYOS® (denosumab injection) and TUZEMTY® (denosumab injection) have joined Organon’s growing biosimilars portfolio in Canada, which spans five therapeutic areas, including oncology, and includes products with more than nine years of market experience.
“The availability of BILDYOS® and TUZEMTY® marks an important step in our collaboration with Organon,” said Darius Panaligan, Chief Commercial Officer, International Markets of Henlius. “Together, we’ve translated our shared vision into tangible outcomes, helping to bring new treatment options to patients in Canada and reinforcing our joint commitment to long-term access.”
These product launches reflect Organon’s long-standing commitment to expanding access to cost-effective treatments and advancing women’s health through a patient-centered approach.
“The addition of new approved denosumab therapies help reinforce a resilient healthcare system and supports clinicians and patients in navigating osteoporosis treatment options with greater flexibility,” said Dr. Famida Jiwa, President and CEO, Osteoporosis Canada.
In 2022, Henlius entered into a license and supply agreement with Organon, granting Organon the exclusive commercialization rights to several biosimilars, including BILDYOS® (denosumab injection) and TUZEMTY® (denosumab injection). The agreement covers exclusive global commercialization rights except for China.
For more information about these products, including important safety information, visit: BILDYOS_PM-E.pdf and TUZEMTY_PM-E.pdf
About Organon
Organon (NYSE: OGN) is a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. With a portfolio of over 70 products across Women’s Health, Biosimilars and General Medicines, Organon focuses on addressing health needs that uniquely, disproportionately or differently affect women, while expanding access to essential treatments in over 140 markets. For more information, visit https://www.organon.com/canada-en/ and connect with us on LinkedIn.
About Henlius
Shanghai Henlius Biotech, Inc. (2696.HK) is a global, innovation-driven biopharmaceutical company committed to delivering high-quality, affordable biologic therapies to patients worldwide. The Company focuses on major disease areas including oncology, autoimmune diseases, and ophthalmic diseases. Founded in 2010, Henlius has established an integrated, end-to-end biopharmaceutical platform encompassing global R&D, clinical operations, regulatory affairs, manufacturing, and commercialisation. The Company employs nearly 4,000 people globally and operates across multiple regions, including China, the United States, and Japan. Leveraging the stable cash flow generated from its biosimilar portfolio to support innovation, Henlius is steadily advancing into its “Globalisation 2.0” phase, building a scalable and sustainable global growth model. As of early 2026, Henlius has achieved regulatory approvals for 10 products across over 60 countries and regions worldwide, including eight approvals in China. The Company has also reached multiple milestones in major biopharmaceutical markets, with four products approved by the U.S. Food and Drug Administration (FDA) and five products approved by the European Commission (EC), reflecting its globally aligned R&D capabilities, quality systems, and manufacturing standards.
Driven by innovation, Henlius has built a diversified, platform-based technology ecosystem through coordinated R&D efforts across Shanghai, the United States, and other regions. Its innovation platforms span immune checkpoint inhibitors, immune cell engager technologies (including multispecific T cell engagers), antibody-drug conjugates (ADCs), and AI-enabled early discovery platforms. The Company currently has more than 50 early-stage innovative assets, approximately 70% of which are expected to be best-in-class, with over 30 clinical trials ongoing globally. Henlius’ core product, serplulimab (trade name: Hetronifly® in Europe), is the world’s first anti–PD-1 mAb approved for first-line treatment of small cell lung cancer and has been approved in 50 markets worldwide with an accelerated globalisation process. In parallel, multiple high-potential innovative assets—including the PD-L1 ADC HLX43 and the novel epitope anti-HER2 mAb HLX22—are advancing through global pivotal clinical development. Supported by a biologics manufacturing network with a total capacity of 84,000L and GMP certifications from regulatory authorities in China, Europe, and the United States, Henlius has established a stable global supply system serving six continents. Guided by a patient-centred mission, Henlius remains focused on addressing unmet medical needs and translating scientific innovation into meaningful clinical value and patient access, contributing sustainably to the global biopharmaceutical ecosystem.
To learn more about Henlius, visit https://www.henlius.com/en/index.html and connect with us on LinkedIn at https://www.linkedin.com/company/henlius/.
1 What is osteoporosis? Osteoporosis Canada. 2024. Accessed April 27, 2026. https://osteoporosis.ca/what-is-osteoporosis/
New capabilities deliver identity-attributed visibility into AI tool usage across endpoints and networks, without additional agents or infrastructure
BURLINGTON, Mass.--(BUSINESS WIRE)--N-able, Inc. (NYSE: NABL), a global cybersecurity company delivering end-to-end business resilience, today announced the availability of Shadow AI Visibility across its Unified Endpoint Management (UEM) solutions, N‑central and N‑sight, and its Security Operations platform, Adlumin. The new capability helps organizations identify, classify, and monitor AI tool usage across managed environments, providing IT and security teams with the visibility needed to address a rapidly growing operational and security blind spot.
As AI adoption accelerates, employees are increasingly using AI-powered applications, browser extensions, developer tools, APIs, and SaaS platforms outside traditional governance processes. “A Gartner® survey of 302 cybersecurity leaders in March – May 2025 revealed that 69% of organizations suspect or have evidence that employees are using prohibited public GenAI.1” This "shadow AI" activity can introduce security, compliance, and operational challenges when organizations lack visibility into which tools are being used, by whom, and where.
Shadow AI Visibility extends N-able's AI-powered cybersecurity solutions by helping customers identify AI usage across endpoints and network activity without requiring additional agents, tools, or management consoles. Available through N-central, N-sight, and Adlumin, the capability enables organizations to build a clearer inventory of AI tools in use and take a more informed approach to AI governance.
"Organizations are embracing AI at an unprecedented pace, but many IT and security teams are struggling to answer a basic question: what AI tools are actually being used across their environment?" said Nicole Reineke, Chief AI Officer, N-able. "Shadow AI Visibility helps close that gap by providing actionable transparency into AI usage across endpoints and networks. Before organizations can govern AI, they need to understand where it's being used. This capability gives customers the foundation they need to make informed decisions around security, compliance, and responsible AI adoption."
Shadow AI Visibility delivers:
Visibility across endpoints and networks to identify AI applications, browser extensions, developer tools, command-line interfaces, and AI-related network activity. Classification and governance insights that organize detected AI tools by category, vendor, model family, and approval status. Identity and device attribution that helps teams understand which users, devices, and processes are interacting with AI services. Integrated workflows within N-central, N-sight, and Adlumin, enabling customers to view, query, report on, and act on AI usage data through the platforms they already use. For managed service providers (MSPs), the capability also creates opportunities to support customers with AI governance initiatives, including usage assessments, risk reviews, compliance reporting, and policy recommendations.
“AI is opening up real opportunities for our business and our clients, but it also requires us to take a more thoughtful approach to oversight and risk," said Aaron Betts, President & CEO, Intelesys. "With Shadow AI Visibility, we can better understand how AI is showing up across not only our environment but our clients as well, and use that insight to guide smarter decisions around security, compliance, and responsible use.”
By helping customers establish an inventory of AI tools and usage patterns, Shadow AI Visibility provides a starting point for developing AI governance strategies without adding operational complexity. To learn more about building an effective AI governance framework, download N-able's guide, AI Governance 101, here.
Shadow AI is available now for N-central, N-sight, and Adlumin, to learn more please visit: www.n-able.com/products.
Gartner Press Release, Gartner Identifies Critical GenAI Blind Spots That CIOs Must Urgently Address, November 2025. GARTNER is a trademark of Gartner, Inc. and/or its affiliates. About N-able
N-able protects businesses from evolving cyberthreats. Our AI powered cybersecurity platform delivers business resilience to more than 500,000 organizations worldwide, leveraging advanced end-to-end capabilities, simplified workflows, market leading integrations, and flexible deployment options to improve efficiency and drive critical security outcomes. Our partner-first approach pairs our technology with experts, training, and peer-led events that empower customers to be secure, resilient, and successful. n-able.com
The N-able trademarks, service marks, and logos are the exclusive property of N-able Solutions ULC and N-able Technologies Ltd. All other trademarks are the property of their respective owners.
Key Takeaways Iron Mountain's recurring storage revenues and pricing supported strong first-quarter 2026 growth. IRM's data center revenues jumped 47.1% as leasing stayed strong and utilization remained high.IRM grew digital and asset lifecycle businesses over 50% year over year, boosting service revenues. Iron Mountain Incorporated (IRM - Free Report) shares have rallied 30.2% in the past three months compared with the industry’s growth of 10.2%.
Iron Mountain’s recurring storage rental revenues remain resilient through pricing and strong retention, while rapid data center expansion, robust leasing demand, and growing digital and asset lifecycle management businesses continue to drive growth and diversify revenues beyond traditional records storage.
Analysts seem bullish on this Zacks Rank #3 (Hold) stock. The Zacks Consensus Estimate for its 2026 AFFO per share has been revised northward by 13 cents to $5.85 over the past two months.
Image Source: Zacks Investment Research
Factors Behind IRM Stock’s Price SurgeIron Mountain continues to rely on highly recurring storage rental revenues, supported by pricing, revenue management and strong customer retention. In the first quarter of 2026, consolidated storage rental revenues increased 15.4% year over year, while Global RIM storage rental grew 8.7%. These results indicate that pricing and revenue management continue to help offset gradual declines in physical storage volumes. Management also highlighted that the physical records storage business delivered its best quarterly growth in years, helping fund investment in faster-growing offerings.
The Global Data Center business remains Iron Mountain's primary growth engine, benefiting from sustained enterprise and hyperscale demand for secure, interconnected capacity. In the first quarter of 2026, data center revenues increased 47.1% year over year to $254.7 million, driven primarily by 46% increase in storage rental revenues, while adjusted EBITDA margin remained above 50% at 52.1%. The operating portfolio reached 507.2 megawatt (MW) from 424.2 MW a year ago and was 97.2% leased, reflecting strong utilization. Leasing activity remained healthy, with 21,849 kilowatt (KW) of new and expansion leases signed during the quarter.
Management reported 32 MW of data center leasing from the beginning of the year through April 2026, suggesting demand carried into the early second quarter. Churn remained low at 0.4%, while cash mark-to-market was 12%, pointing to pricing power on renewals. The development pipeline also expanded, with 181.5 MW under construction and 684.2 MW held for future development, bringing total potential data center capacity to 1.37 gigawatt (GW). This robust pipeline supports the company’s strategy to build and energize capacity ahead of demand and sustain high growth rates as more sites come online.
Iron Mountain is broadening beyond traditional records storage through digital and asset lifecycle management capabilities that management is increasingly cross-selling across its large customer base. Management said that the data center, digital and ALM businesses grew more than 50% year over year in first-quarter 2026, while consolidated service revenues rose 30.6% year over year to $841 million.
Within Global RIM, service revenues increased 16.5% year over year, indicating healthy demand for higher-value services alongside storage. Recent acquisitions in IT asset disposition and logistics capabilities extend the lifecycle offering set and deepen customer relationships, which can improve wallet share over time, even as paper-based workflows evolve. The company’s global footprint and broad customer mix also help scale these newer offerings across regions and industries.
Key Concerns for Iron MountainCompetition from other industry players is likely to lead to aggressive pricing pressure and hurt Iron Mountain’s prospects. High interest expenses and adverse foreign currency movements remain a concern.
Stocks to ConsiderSome better-ranked stocks from the broader REIT sector are Lamar Advertising (LAMR - Free Report) and Vornado Realty Trust (VNO - Free Report) , each carrying a Zacks Rank of 2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Consensus Estimate for LAMR’s 2026 FFO per share is pegged at $8.81, which indicates year-over-year growth of 6.66%.
The Zacks Consensus Estimate for VNO’s full-year FFO per share is pinned at $2.34, which calls for an increase of 0.86% from the year-ago period.
Note: Anything related to earnings presented in this write-up represents FFO, a widely used metric to gauge the performance of REITs.
Toronto, June 22, 2026 (GLOBE NEWSWIRE) -- New home buyers in the Greater Toronto Area (GTA) continue to respond positively to the enhanced HST rebate program as low-rise new home sales outperformed its 10-year average for a second consecutive month in May, the Building Industry and Land Development Association (BILD) said today. The HST rebate program remains a historic buying opportunity for those looking to purchase a new home. However, in May the need for clarity on how rebates are administered contributed to some potential buyers delaying purchasing decisions.
There was a total of 1,023 new home sales in May, up significantly from the record May low of 2025 but 57 per cent below the 10-year average, according to Altus Group*, BILD’s official source for new home market intelligence. Historically, total new home sales for a typical May in the GTA would be 2,353 units based on the previous 10-year average.
“GTA new home sales in May continued to respond positively to the HST rebate program, led by the single-family sector which surpassed its 10-year average for the second consecutive month,” said Edward Jegg, Research Manager at Altus Group. “However, condominium apartment sales have not to date benefitted from the rebate program for two main reasons: much of the existing product is locked into legacy pricing with higher costs; and any new high-rise projects are unlikely to be able to meet the “substantially completed” requirement of the HST rebate program.”
Condominium apartments, including units in low, medium, and high-rise buildings and stacked townhouses, accounted for 193 units sold in the GTA in May, 89 per cent below the 10-year average.
There were 830 single-family home sales in the GTA in May, a significant year-over-year increase and 26 per cent above the 10-year average. Single-family homes include detached, linked, and semi-detached houses and townhouses (excluding stacked townhouses).
Total new home remaining inventory in the GTA dipped below the 20,000 mark for the third time in 24 months with 18,763 units for May. This includes 13,138 condominium apartment units and 5,625 single-family dwellings. This represents a combined inventory level of 32 months, based on average sales for the last 12 months.
When sales increase after a prolonged period of very low sales, the months of inventory statistics should be viewed with caution as it is based on dividing present inventory by the average of the past 12 months of sales activity (which have been very low). We anticipate that as sales increase, the months of inventory statistics will decrease rapidly.
“It is encouraging to see the continuous positive momentum for low-rise new home sales in the GTA,” said Justin Sherwood, Chief Operating Officer at BILD. “While new single-family home sales surpassed the 10-year average for a second straight month, they did slightly decrease from the sales levels we saw in April 2026 – the first month that the HST rebate program was introduced. This decrease is largely due to potential new homebuyers still waiting on the sidelines for clarity on how the HST rebate will be administered. For the high-rise sector, condominiums continue to struggle with higher existing inventory, a price floor and very low new product launches (only one new condo project has launched in 2026). In addition, the HST rebate program eligibility requirements have defined start and completion dates for new housing projects that are too tight for most new high-rise condominium projects to meet, which is likely also impacting sales. Providing clarity on these details will ensure that the momentum experienced since April continues.”
The benchmark price for new condominium apartments in May in the GTA was $1,029,489, remaining at an apparent price floor. The benchmark price for new single-family homes was $1,427,543, which was down 5.2 per cent over the last 12 months. These are gross prices, not reflective of any HST rebate, in order to facilitate a like-on-like comparison with previous years. Purchasers who qualify for an HST rebate would realize additional benefit from this rebate.
In Simcoe County in May, there were 56 single-family new home sales and no condominium apartment sale, with the weighted average price of the single-family new homes in Simcoe County at $1,143,359.
With more than 1,000 member companies, BILD is the voice of the home building, residential and non-residential land development and professional renovation industries in the Greater Toronto Area. The building and renovation industry provides 256,000 jobs in the region and $39.3 billion in investment value. BILD is affiliated with the Ontario and Canadian Home Builders’ Associations.
-30-
For additional information or to schedule an interview, contact Nadine Habib at [email protected] (416-617-7994)
*Altus Group should be credited as BILD’s official source of new home market intelligence.
BILD New Home Sales - Media Backgrounder - May 2026 - Altus Data Solutions - FINAL
MILWAUKEE--(BUSINESS WIRE)--Zurn Elkay Water Solutions Corporation (NYSE: ZWS) has been named one of America’s High-Growth Companies 2026 for the first time by Business Insider and Plant-A Insights Group. Among the 500 companies on the list, Zurn Elkay is one of only 50 manufacturers and one of only six Wisconsin-based companies.
“With clean, safe water at the heart of our business, our growth strategy and our sustainability strategy are increasingly the same,” said Todd A. Adams, Chairman and CEO of Zurn Elkay Water Solutions.
Share “With clean, safe water at the heart of our business, our growth strategy and our sustainability strategy are increasingly the same,” said Todd A. Adams, Chairman and CEO of Zurn Elkay Water Solutions. “The world is facing escalating water conservation and contamination issues, and we’ve built a core business uniquely positioned to meet those challenges with solutions that make water safe and more sustainable. Whether it’s drinking water filtration that reduces forever chemicals and other emerging contaminants or backflow preventers that stop contaminated water from entering the potable water system, each new innovation reflects our unwavering commitment to protecting the world’s most vital resource while creating lasting value for our customers and shareholders.”
Business Insider's America's High-Growth Companies 2026 is based on an extensive assessment of financial records against 11 financial growth metrics for over 3,000 US publicly listed companies on the New York Stock Exchange (NYSE) and Nasdaq. Companies were evaluated on their ability to maintain high-quality growth, and eligibility was restricted to companies that have been public since 2020 and achieved both a minimum revenue of $100 million and profitability in fiscal year 2025.
Zurn Elkay’s financial performance has also been recognized by TIME in its lists of America’s Growth Leaders (2025-2026) and World’s Best Companies for Sustainable Growth (2025-2026). The company has earned recognition from Newsweek in its list of America’s Most Responsible Companies (2021-2026), the World’s Greenest Companies (2026) and America’s Greenest Companies (2025-2026), as well as Barron’s 100 Most Sustainable Companies (2026).
To learn more about Zurn Elkay Water Solutions and its sustainability efforts, including the company’s most recent sustainability report, visit zurnelkay.com/sustainability.
About Zurn Elkay Water Solutions
Named one of the World’s Greenest Companies and one of America’s Most Responsible Companies by Newsweek and one of the World’s Best Companies for Sustainable Growth by TIME, Zurn Elkay Water Solutions is headquartered in Milwaukee, Wisconsin, and is a growth-oriented, pure-play water management business that designs, procures, manufactures and markets what we believe to be the broadest sustainable product portfolio of specification-driven water management solutions to improve health, hydration, human safety and the environment. The Zurn Elkay product portfolio includes professional grade water safety and control products, flow systems products, hygienic and environmental products and filtered drinking water products for public and private spaces. Learn more at zurnelkay.com.
Cautionary Statement on Forward-Looking Statements
Information in this release may involve outlook, expectations, beliefs, plans, intentions, strategies or other statements regarding the future, which are forward-looking statements. These forward-looking statements involve risks and uncertainties. All forward-looking statements included in this release are based on information available to Zurn Elkay Water Solutions as of the date of this release, and Zurn Elkay Water Solutions assumes no obligation to update any such forward-looking statements. The statements in this release are not guarantees of future performance, and actual results could differ materially from current expectations. Numerous factors could cause or contribute to such differences. Please refer to “Risk Factors” and “Cautionary Notice Regarding Forward-Looking Statements” in our report on Form 10-K for the period ended December 31, 2025, as well as the Company’s subsequent annual, quarterly and current reports filed on Forms 10-K, 10-Q and 8-K from time to time with the Securities and Exchange Commission for a further discussion of the factors and risks associated with the business.
More News From Zurn Elkay Water Solutions Corporation
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.
Zacks Premium also includes the Zacks Style Scores.
What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.
Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.
Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.
#1 (Strong Buy) stocks have produced an unmatched +24% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.
This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.
That's where the Style Scores come in.
To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.
Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Kennametal (KMT - Free Report) Based in Latrobe, PA, Kennametal Inc. is a manufacturer, marketer and distributor of high-speed metal cutting tools, tooling systems and wear-resistant parts. Its products are marketed through a number of channels to the end users, comprising manufacturers of machine tools, transportation vehicles and various components, airframe, aerospace components, machinery (light and heavy), components (energy-related), and others. Also, the company’s products are used by manufacturers and suppliers in the oil and gas exploration, road construction, and other industries.
KMT is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.
It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 10.86; value investors should take notice.
For fiscal 2026, two analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.80 to $3.23 per share. KMT boasts an average earnings surprise of +18.6%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, KMT should be on investors' short list.
NEW YORK, June 21, 2026 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Manhattan Associates, Inc. (NASDAQ: MANH).
If you currently own shares of Manhattan Associates stock, please visit the firm’s website at https://rosenlegal.com/submit-form/?case_id=35966 for more information. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected].
Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827 [email protected]
www.rosenlegal.com
, /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Manhattan Associates, Inc. (NASDAQ: MANH).
If you currently own shares of Manhattan Associates stock, please visit the firm's website at https://rosenlegal.com/submit-form/?case_id=35966 for more information. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected].
Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
, /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Manhattan Associates, Inc. (NASDAQ: MANH).
If you currently own shares of Manhattan Associates stock, please visit the firm's website at https://rosenlegal.com/submit-form/?case_id=35966 for more information. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected].
Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com
Key Takeaways U.S. equities remain resilient in 2026 despite Fed, yield, oil, geopolitical and trade policy risks.CACI has expected sales growth of 10.6% for fiscal 2027, supported by federal customer groups.GL and KNX are projected to grow sales 6.3% and 7.1% in 2026, backed by core business segments. U.S. equities have remained resilient so far this year, although performance has been highly uneven. After rebounding from early-period volatility, markets have pushed higher, backed by solid corporate earnings, AI-led optimism and a still-supportive economic backdrop. Offsetting these are broader geopolitical and macroeconomic concerns like the Federal Reserve’s hawkish stance, Treasury-yield swings, oil-price volatility, geopolitical risks, particularly tensions in the Middle East, and evolving trade policies.
Amid such an operating environment, the traditional way of selecting stocks is a good idea. Sales growth provides a more reliable view for evaluating stocks compared with earnings-focused metrics. In this regard, stocks like CACI International Inc. (CACI - Free Report) , Globe Life Inc. (GL - Free Report) and Knight-Swift Transportation Holdings Inc. (KNX - Free Report) are worth buying.
Sales growth is among the most reliable indicators of a company’s underlying business momentum. While earnings can be affected by cost structures, accounting items and other non-operating factors, revenues offer a clearer view of customer demand and the company’s ability to sell more products or services. Sustained sales growth may signal healthy end-market conditions, market-share gains, pricing power, successful product launches, or expansion into new geographies and customer segments.
Revenue growth can also provide a foundation for stronger profitability. As sales increase, companies may be able to spread fixed costs across a larger revenue base, improving operating leverage and supporting margin expansion over time. Yet, sales growth should not be assessed in isolation. It is most meaningful when viewed alongside industry trends, peer performance, pricing dynamics, customer mix and the broader macroeconomic environment.
The quality and durability of sales growth are equally important. Recurring revenues, repeat purchases, volume-driven gains and sustainable demand are generally more valuable than growth fueled by temporary factors. Companies that consistently deliver high-quality sales growth across market cycles are often better positioned to generate dependable cash flows, reinvest in the business, strengthen their competitive position and create long-term shareholder value.
Selecting the Potential Winning StocksTo shortlist stocks with impressive sales growth and a high cash balance, we have selected 5-Year Historical Sales Growth (%) greater than X-Industry and Cash Flow of more than $500 million as our main screening parameters.
But sales growth and cash strength are not the absolute criteria for selecting stocks. Hence, we have added other factors to arrive at a winning strategy.
P/S Ratio less than X-Industry: This metric determines the value placed on each dollar of a company’s revenues. The lower the ratio, the better it is for picking a stock since the investor is paying less for each unit of sales.
% Change F1 Sales Estimate Revisions (four weeks) greater than X-Industry: Estimate revisions, better than the industry, are often seen to trigger an increase in stock price.
Operating Margin (average last five years) greater than 5%: The operating margin measures how much every dollar of a company's sales translates into profits. A high ratio indicates that the company has good cost control and sales are increasing faster than costs — an optimal situation.
Return on Equity (ROE) greater than 5%: This metric will ensure that sales growth is translated into profits and the company is not hoarding cash. A high ROE means that the company is spending wisely and is, in all likelihood, profitable.
Zacks Rank less than or equal to 2: Zacks Rank #1 (Strong Buy) or 2 (Buy) stocks are known to outperform, irrespective of the market environment. You can see the complete list of today’s Zacks #1 Rank stocks here.
3 Stocks With Solid Sales Growth to Invest InBased in Reston, VA, CACI International delivers IT applications and infrastructure to improve communications and secure the integrity of information systems and networks, enhance data collection and analysis, and increase efficiency and mission effectiveness. CACI earns its revenues through four customer groups: Department of Defense, Intelligence Community, Federal Civilian Agencies and Commercial and Other.
CACI’s expected sales growth rate for fiscal 2027 is 10.6%. CACI International carries a Zacks Rank #2 at present.
Based in McKinney, TX, Globe Life is an insurance holding company for a group of insurance companies that market primarily individual life and supplemental health insurance to lower-middle to middle-income households throughout the United States. GL’s business is organized into four segments: Life Insurance, Supplemental Health Insurance, Annuities and Investments.
Globe Life's expected sales growth rate for 2026 is 6.3%. GL currently carries a Zacks Rank #2.
Phoenix, AZ-based Knight-Swift Transportation is one of North America's largest and most diversified freight transportation companies, providing multiple full truckload, LTL, intermodal and other complementary services. KNX utilizes a nationwide network of business units and terminals across the United States and Mexico to serve customers throughout North America.
KNX’s sales are expected to rise 7.1% in 2026. Knight-Swift Transportation carries a Zacks Rank #2 at present.
WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of GoDaddy Inc. (NYSE: GDDY) resulting from allegations that GoDaddy may have issued materially misleading business information to the investing public.
SO WHAT: If you purchased GoDaddy securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.
WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/cases/godaddy-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
WHAT IS THIS ABOUT: Rosen Law Firm is investigating potential civil securities claims.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. At the time Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827 [email protected]
www.rosenlegal.com
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of GoDaddy Inc. (NYSE: GDDY) resulting from allegations that GoDaddy may have issued materially misleading business information to the investing public.
So What: If you purchased GoDaddy securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.
What to do next: To join the prospective class action, go to https://rosenlegal.com/cases/godaddy-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
What is this about: Rosen Law Firm is investigating potential civil securities claims.
Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. At the time Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.
Zacks Premium includes access to the Zacks Style Scores as well.
What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.
Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.
The Style Scores are broken down into four categories:
Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.
Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.
Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.
VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.
Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +24% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.
That's where the Style Scores come in.
To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.
The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.
A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: GoDaddy (GDDY - Free Report) GoDaddy’s solutions serve roughly 20 million customers that include independents, WebPros, Domain Registrars and Investors, and Third-Party Registrars and Corporate Domain Portfolio owners.
GDDY is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.
It also boasts a Value Style Score of A thanks to attractive valuation metrics like a forward P/E ratio of 10.51; value investors should take notice.
Four analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.08 to $7.14 per share. GDDY also boasts an average earnings surprise of +6.1%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, GDDY should be on investors' short list.
WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GoDaddy Inc. (NYSE: GDDY) resulting from allegations that GoDaddy may have issued materially misleading business information to the investing public.
SO WHAT: If you purchased GoDaddy securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.
WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/cases/godaddy-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
WHAT IS THIS ABOUT: Rosen Law Firm is investigating potential civil securities claims.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. At the time Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827 [email protected]
www.rosenlegal.com
PITTSBURGH--(BUSINESS WIRE)--Wabtec Corporation (NYSE: WAB) announced it will report 2026 second quarter results before the U.S. financial markets open on July 22, 2026. The company will conduct a conference call to discuss those results with analysts and investors at 8:30 a.m. ET the same day. To listen to the call via webcast, visit Wabtec’s website at www.WabtecCorp.com and click on “Events & Presentations” in the “Investor Relations” section. An audio replay of the call will be available by calling 1-855-669-9658 or 1-412-317-0088 (access code: 2758919).
About Wabtec Corporation
Wabtec Corporation is revolutionizing the way the world moves for future generations. The Company is a leading global provider of equipment, systems, digital solutions and value-added services for the freight and transit rail industries, as well as the mining, marine and industrial markets. Wabtec has been a leader in the rail industry for over 155 years and has a vision to achieve a sustainable rail system in the U.S. and worldwide. Visit Wabtec’s website at www.wabteccorp.com.
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, June 23:
Cboe Global Markets, Inc. (CBOE - Free Report) : This derivatives and securities exchange network carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 8.8% over the last 60 days.
Cboe has a PEG ratio of 1.11 compared with 1.60 for the industry. The company possesses a Growth Score of A.
Centene Corporation (CNC - Free Report) : This managed care company carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 15.3% over the last 60 days.
Centene has a PEG ratio of 0.47 compared with 1.06 for the industry. The company possesses a Growth Score of A.
Credo Technology Group Holding Ltd (CRDO - Free Report) : This high-speed connectivity solutions company carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 20.5% over the last 60 days.
Credo Technology has a PEG ratio of 1.16 compared with 1.39 for the industry. The company possesses a Growth Score of B.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Learn more about the Growth score and how it is calculated here.
NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.
To view the full publication, “Next-Generation DNA Repair Therapies Open New Frontiers in Oncology,” please visit: https://ibn.fm/LL2Es
Cancer research is entering one of its most dynamic periods in decades. The class of drugs known as DNA Damage Response inhibitors (“DDRi”), which work by blocking cancer cells’ ability to repair their own damaged DNA, is expanding rapidly beyond its original anchor, the PARP inhibitor. DDRi therapies collectively represented an estimated $7-plus billion in global sales in 2025, and the broader oncology, diagnostics and precision medicine markets are projected to climb to roughly $750 billion by 2030.
New inhibitor classes are emerging as the next major wave. Sitting at the forefront of this shift is Onco-Innovations Limited, a Canadian clinical-stage oncology company developing ONC010(TM), a nanoparticle-encapsulated PNKP inhibitor that targets a DNA repair enzyme involved in multiple DNA repair pathways. As the field races to find the next generation of synthetic lethality assets, Onco-Innovations occupies a unique space as it strengthens its position in the biopharmaceutical and biotechnology sector.
About Onco-Innovations Limited
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco’s mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumors.
For further information, please visit the company’s website at www.OncoInnovations.com.
NOTE TO INVESTORS: The latest news and updates relating to ONNVF are available in the company’s newsroom at https://ibn.fm/ONNVF
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
DISCLAIMER: BioMedWire (BMW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by BMW are solely those of BMW. Readers of this Article and content agree that they cannot and will not seek to hold liable BMW for any investment decisions by their readers or subscribers. BMW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.
The Article and content related to the profiled company represent the personal and subjective views of the Author and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, BMW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.
BMW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BMW undertakes no obligation to update such statements.
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
Key Takeaways CBOE grew Q1 net revenue 29% to $728.9M, led by a 32% increase in derivatives revenue.Cboe's SPX options reached record volume, while Data Vantage revenue climbed to $181.3M.CBOE is cutting costs through restructuring and had $569.4M remaining for share repurchases. Cboe Global Markets, Inc. (CBOE - Free Report) shares have lost 28.4% over the past month compared with the industry's decline of 10%.
The stock has been weighed down by concerns over its valuation compression, competitive threats, and selling pressure after a strong rally that reached a 52-week high in May. Investor sentiment has also been affected by market-share erosion and expectations of lower market volatility that could reduce trading activity. However, the solid earnings growth, record trading volumes, a profitable derivatives and market-data business, and prudent capital deployment position the company well for long-term growth.
Shares of some of its peers, including Intercontinental Exchange Inc. (ICE - Free Report) , CME Group Inc. (CME - Free Report) , and Nasdaq, Inc. (NDAQ - Free Report) , have lost 14.1%, 15.8% and 9.2%, respectively, in the past month.
1-Month Price Performance: CBOE, ICE, CME, NDAQ & Industry
Image Source: Zacks Investment Research
CBOE’s Average Target Price Suggests UpsideBased on short-term price targets offered by 14 analysts, the Zacks average price target is $317.50 per share. The average suggests a potential 24% upside from the last closing price.
Image Source: Zacks Investment Research
CBOE ValuationShares of Cboe Global are currently trading at a discount. Its forward price-to-earnings (P/E) ratio is 18.69X, which is below the industry average of 18.72X.
Image Source: Zacks Investment Research
Shares of Intercontinental Exchange are trading at a discount, while CME and Nasdaq are trading above the industry average.
CBOE’s Growth Projection EncouragesThe Zacks Consensus Estimate for Cboe Global’s 2026 earnings per share (EPS) indicates a year-over-year increase of 25%. The consensus estimate for revenues is pegged at $2.75 billion, implying a year-over-year improvement of 13.1%.
The consensus estimate for 2027 EPS and revenues indicates an increase of 5.5% and 2.9%, respectively, from the corresponding 2026 estimates.
Earnings have grown 14.7% in the past five years, better than the industry average of 10.6%. The expected long-term earnings growth rate is 16.8%, %, better than the industry average of 12.2%. It also has a Growth Score of A.
Optimist Analyst Sentiment on CBOE10 analysts covering the stock have raised estimates for 2026 and 2027 over the past 60 days, with no downward revisions. Thus, the Zacks Consensus Estimate for 2026 and 2027 earnings has moved up 8.8% and 9.1%, respectively, over the same period.
CBOE’s Favorable Return on CapitalReturn on equity for the trailing-12 months was 24.9%, which compared favorably with the industry’s average of 16%. This reflects its efficiency in utilizing shareholders’ funds.
Return on invested capital in the trailing-12 months was 14.6%, better than the industry average of 6.7%, reflecting CBOE’s efficiency in utilizing funds to generate income.
What Drives CBOE’s Growth?Cboe Global’s organic strength lies in a diversified business mix that ensures uninterrupted revenue generation and recurring non-transaction revenues. The company is sharpening its focus on core derivatives, data, clearing and off-exchange businesses through portfolio optimization, including the planned sale of its Canada and Australia operations. At the same time, CBOE is investing in high-growth opportunities such as prediction markets, tokenized products and expanded clearing services.
Trading activity across Cboe’s derivatives complex continues to be the primary organic growth engine. Net revenue rose 29% year over year to $728.9 million, with derivatives net revenue up 32% in the first quarter of 2026. Proprietary SPX options set another quarterly record with average daily volume up 34% year over year to 4.9 million contracts, supported by both shorter-dated and longer-dated demand as market conditions shifted. Management raised its 2026 organic total net revenue growth target to low double-digit to mid-teens.
Growing demand for market data, connectivity services and analytics solutions is driving solid growth in the Data Vantage segment. In the first quarter of 2026, Data Vantage revenue increased to $181.3 million from $152.5 million a year ago, supported primarily by new customer additions and increased product adoption. Management lifted its 2026 Data Vantage organic net revenue growth target to low double-digit.
The multi-quarter realignment is now paired with additional actions aimed at reducing complexity and improving execution. Management expects these initiatives to reduce its workforce by approximately 20% and be substantially completed by the end of 2026. Management also lowered 2026 expense guidance and expects meaningful savings from restructuring initiatives.
CBOE’s strategic investments are well supported by solid capital management. The company has been strengthening its balance sheet with a strong cash position supporting continued investment in technology, sales and product initiatives as well as capital returns, while lowering its debt balance. As of March 31, 2026, it had $569.4 million remaining under existing share repurchase authorizations.
ConclusionCboe Global’s growth strategy of expanding its product line across asset classes, broadening geographic reach, diversifying the business mix with recurring revenues, and leveraging technology reflects its operational expertise. A VGM Score of B instils optimism.
Coupled with cheap valuation, optimistic analyst sentiment, favorable ROE and favorable growth estimates, the time appears right for potential investors to bet on this Zacks Rank #1 (Strong Buy) insurer. You can see the complete list of today’s Zacks #1 Rank stocks here.
, /PRNewswire/ -- Cboe Global Markets, Inc. (Cboe: CBOE), a leading global markets operator and pioneer in equity and index derivatives, today announced the launch of the first products in its new prediction markets suite, Cboe PredictsSM.
The offering includes binary option contracts based on the Mini-S&P 500 Index (XSP), listed under the symbols XSPBW and XSPBX. The contracts are now available on Interactive Brokers and expected to roll out at Charles Schwab in the coming months, with additional retail brokerage platforms expected to offer access over time.
Cboe PredictsSM represents the latest expansion of Cboe's S&P 500 Index (SPX) product suite. XSP allows customers to trade on the performance of the S&P 500 Index (SPX) but is scaled to 1/10th the size of SPX – making it a smaller, more retail-friendly alternative. Traders can express a view on where XSP may close by taking a "yes" position (paying $100 if the index settles at or above a specified level, or $0 otherwise) or a "no" position (paying $100 if it settles below that level, or $0 otherwise).
"Following the success of SPX 0DTE options, we have seen continued customer demand for shorter-dated, outcome-based trading, creating a natural extension for Cboe to introduce XSP binary options," said JJ Kinahan, Head of Retail Expansion and Alternative Investment Products at Cboe. "Cboe's S&P 500 options suite has long provided traders with flexibility to define their outcomes through traditional options strategies. With Cboe Predicts, we are expanding that choice by offering simple 'yes-or-no' payout event contracts, supported by dedicated educational resources designed to help customers participate more confidently and responsibly."
In a future release, Cboe also plans to enable trading of XSP vertical spreads through its proprietary, patent-pending Quoted Spread BookSM (QSBSM) framework. The framework is designed to package widely used options strategies into a simpler, more intuitive format, helping newer traders already comfortable with "yes/no" outcomes build familiarity with more advanced options concepts within defined-risk strategies.
Through access provided by leading retail brokers, Cboe's intermediated model is designed to encompass high standards for customer education, market access and oversight. Additionally, these securities-based products are centrally cleared through the Options Clearing Corporation (OCC), providing enhanced risk management during the settlement process.
"OCC stands ready to bring the same clearing infrastructure and risk management discipline that underpins all of the products we clear to the new binary options," said Mike Hansen, Chief Clearing and Settlement Services Officer at OCC. "Our commitment to operational excellence and financial integrity ensures that participants can engage with confidence, knowing every transaction is supported by sound, well-established clearing and settlement services."
"Investors increasingly seek products that allow them to express a specific view on future events and market outcomes," said Milan Galik, Chief Executive Officer of Interactive Brokers. "Cboe's binary options and Mini-S&P 500 Index contracts provide another way to do that, and we are pleased to make them available to Interactive Brokers clients."
"We support approaches that bring transparency, defined risk, and investor education to financial-related prediction markets," said James Kostulias, Head of Trading Services, Charles Schwab. "We plan to offer clients access to these binary options contracts in the coming months, building on our existing platform and demand from active traders."
"For more than 50 years, Cboe has built and operated some of the world's most established and trusted markets," said Rob Hocking, Global Head of Derivatives at Cboe. "We look forward to bringing our experience, trusted market infrastructure and the deep liquidity of the SPX options ecosystem to prediction markets. Our goal is to help set a higher standard for market integrity, product design and investor protection by offering access through a regulated securities exchange and central clearing through OCC."
Cboe has also introduced educational resources, including a new prediction markets resource hub and courses through The Options Institute, a leader in options education for more than 40 years. These courses guide learners from market basics and decision-making through Cboe's 'yes/no' contracts, then into core options concepts.
Cboe's XSP prediction market contracts are security options and will trade within the same regulatory framework as U.S.-listed options, providing institutional-grade liquidity, transparency, and surveillance, among other benefits.
About Cboe Global Markets
Cboe Global Markets (Cboe: CBOE) is a leading global markets operator with a long history of innovation in equity and index derivatives. Since launching the world's first listed options exchange in 1973, Cboe has pioneered landmark products, including the introduction of S&P 500® index options and the creation of the VIX® Index, the world's leading gauge of market volatility, reshaping how investors manage risk and access opportunity. Today, Cboe operates derivatives, equities, and FX markets, providing trading, clearing, and investment solutions for customers worldwide. To learn more, visit www.cboe.com.
Cboe Media Contacts
Cboe Analyst Contact
Angela Tu
Tim Cave
Kenneth Hill, CFA
+1-646-856-8734
+44 (0) 7593-506-719
+1-312-786-7559
[email protected]
[email protected]
[email protected]
CBOE-C
CBOE-OE
Cboe®, Cboe Global Markets®, and VIX ® are registered trademarks and Cboe PredictsSM, Quoted Spread BookSM, and QSBSM are service marks of Cboe Exchange, Inc., and S&P 500® is a registered trademark of Standard & Poor's Financial Services LLC. All other trademarks and service marks are the property of their respective owners.
Cautionary Statements Regarding Forward-Looking Information
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. You can identify these statements by forward-looking words such as "may," "might," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," and the negative of these terms and other comparable terminology. All statements that reflect our expectations, assumptions or projections about the future other than statements of historical fact are forward-looking statements. These forward-looking statements, which are subject to known and unknown risks, uncertainties and assumptions about us, may include projections of our future financial performance based on our growth strategies and anticipated trends in our business. These statements are only predictions based on our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from those expressed or implied by the forward-looking statements.
We operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible to predict all risks and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.
Some factors that could cause actual results to differ include: the loss of our right to exclusively list and trade certain index options and futures products; economic, political and market conditions; compliance with legal and regulatory obligations; price and new products and services competition and consolidation in our industry; decreases in trading or clearing volumes, market data fees or a shift in the mix of products traded on our exchanges; legislative or regulatory changes or changes in tax regimes; our ability to protect our systems and communication networks from security vulnerabilities and breaches; our ability to attract and retain skilled management and other personnel; increasing competition by foreign and domestic entities; our business and operational dependence on and exposure to risk from third parties; factors that impact the quality and integrity of our and other applicable indices; our ability to manage our global operations, growth, and strategic acquisitions, wind downs, divestitures, or alliances effectively; increases in the cost of the products and services we use; our ability to operate our business without violating the intellectual property rights of others and the costs associated with protecting our intellectual property rights; our ability to minimize the risks, including our credit, liquidity, market, investment, counterparty, and default risks, associated with operating our clearinghouses; our ability to accommodate trading and clearing volume and transaction traffic, including significant increases, without failure or degradation of performance of our systems; misconduct by those who use our markets or our products or for whom we clear transactions; challenges to our use of open source software code; our ability to meet our compliance obligations, including managing our business interests and our regulatory responsibilities; the loss of key customers or a significant reduction in trading or clearing volumes by key customers; damage to our reputation; the ability of our compliance and risk management methods to effectively monitor and manage our risks; restrictions imposed by our debt obligations and our ability to make payments on or refinance our debt obligations; our ability to maintain an investment grade credit rating; impairment of our goodwill, long-lived assets, investments or intangible assets; the accuracy of our estimates and expectations; and litigation risks and other liabilities. More detailed information about factors that may affect our actual results to differ may be found in our filings with the SEC, including in our Annual Report on Form 10-K for the year ended December 31, 2025 and other filings made from time to time with the SEC.
We do not undertake, and we expressly disclaim, any duty to update any forward-looking statement whether as a result of new information, future events or otherwise, except as required by law. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.
Key Takeaways DGX posted strong physician channel growth and expanded hospital and consumer testing initiatives.DGX saw double-digit AD-Detect blood test revenue growth and expanded oncology MRD offerings.DGX is advancing AI, automation and Project Nova while managing a sizable debt load. Quest Diagnostics (DGX - Free Report) is well-poised for growth in the coming quarters, supported by its continued focus on meeting the evolving needs of its core customers — physicians, hospitals and consumers. The company is seeing continued momentum in Advanced Diagnostics, including the strong uptake of the AD-Detect blood test. Efforts to drive operational improvements through the adoption of AI, automation and other technologies also sound very encouraging. Yet, Quest Diagnostics’ solvency level remains a concern. Macroeconomic pressures can weigh on its operations, too.
Over the past year, this Zacks Rank #3 (Hold) stock has rallied 7.7% compared with the industry’s 8.2% growth and the S&P 500 composite’s 23.2% rise.
The renowned provider of diagnostic information services has a market capitalization of $21.59 billion. Quest Diagnostics has an earnings yield of 5.50%. The company’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 3.50%.
Tailwinds Supporting DGXGrowth Momentum in Base Business: Quest Diagnostics delivered high single-digit growth in physician channel revenues in first-quarter 2026, driven by strong demand for innovative testing solutions, expanded health plan access and enterprise account growth. The company also recorded growth in end-stage renal disease, a newer clinical area focused on lab testing for dialysis patients. Volume growth was driven by Fresenius Medical Care’s dialysis network and contributions from newly added independent dialysis clinics and other providers.
In the hospital channel, the company’s flexible solutions allow customers to free up capital while accessing diagnostic innovation and expertise. In early 2026, Quest Diagnostics began scaling its Co-Lab Solutions, including reference laboratory testing, professional laboratory management services, laboratory workforce and supply-chain management, and analytics across all 21 hospitals of Corewell Health.
Image Source: Zacks Investment Research
The consumer-testing platform, QuestHealth.com, continues to gain strong momentum. Quest Diagnostics is deepening partnerships with leading consumer health and wellness brands like WHOOP and OURA Health, integrating its extensive laboratory testing and technology directly into their mobile platforms.
Strong Potential of Advanced Diagnostics: Quest Diagnostics drives growth across its customer channels through fast-growing, advanced diagnostics spanning five clinical areas — advanced cardiometabolic, autoimmune, brain health, oncology, and women's and reproductive health. In brain health, revenues from the AD-Detect blood test for Alzheimer's disease continued to grow at a double-digit rate in the first quarter of 2026.
The cardiometabolic and endocrine portfolio growth was driven by robust demand for tests of Lp(a) and ApoB, as well as for kidney, liver and reproductive hormones.
In oncology, the company continues to build its presence in blood-based minimal residual disease (MRD) testing. In January 2026, new research presented at the ASCO Gastrointestinal Cancers Symposium highlighted the strong clinical value of Quest Haystack MRD in monitoring colorectal cancer. The company also launched the Flow Cytometry MRD blood test for myeloma.
Operational Excellence, a Strategic Priority: Quest Diagnostics’ Invigorate program consistently targets 2% annual savings through structured plans to drive savings and improve productivity across the value chain. The company is deploying automation and AI technologies to improve quality, service, efficiency and the workforce experience. The new Quest AI Companion tool transforms complex biomarker data and reference ranges on test reports into clear, plain language. Quest Diagnostics is scaling the planning and design work for Project Nova, a multi-year initiative to transform its order-to-cash processes and systems and is on track to implement the first wave of solutions in the fall of 2027.
What Ails DGX?Escalating Debt Level: At the end of the first quarter of 2026, long-term debt totaled $5.16 billion, while the cash and cash equivalent balance was only $393 million. The current portion of the debt was $503 million. Debt-to-capital ratio was 42.5%, down sequentially 1.6%. A higher debt level induces higher interest payments, which come along with the risk of failure to pay the same. The times interest ratio, which indicates the company’s capacity to pay interest, was 6.3% in the quarter.
Unstable Macroeconomic Backdrop: As the U.S. healthcare system continues to evolve, Quest Diagnostics faces several inherent risks. Government payers, such as Medicare and Medicaid, have taken steps to reduce the utilization and reimbursement of healthcare services, including clinical testing services. The industry-wide trend of consolidation has resulted in larger insurance plans with significant bargaining power, making it difficult for Quest Diagnostics to negotiate fee arrangements and possibly limiting access to its newer innovative solutions. With the new U.S. administration in place, any changes in U.S. healthcare regulation could have a material adverse effect on the company’s business.
DGX Stock Estimate TrendThe Zacks Consensus Estimate for Quest Diagnostics’ 2026 earnings per share (EPS) has remained constant at $10.72 in the past 30 days.
The consensus estimate for the company’s 2026 revenues is pegged at $11.83 billion. This suggests 7.2% growth from the year-ago reported number.
Key PicksSome better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Align Technology (ALGN - Free Report) and Integra LifeSciences (IART - Free Report) .
Globus Medical has an earnings yield of 5.9% compared to the industry’s negative 3.5% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 26.3%. GMED shares have rallied 35% against the industry’s 6.3% fall over the past year.
GMED sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Align Technology, sporting a Zacks Rank #1, has an estimated long-term earnings growth rate of 10.3% compared with the industry’s 5.5% growth. Shares of the company have dropped 6.8% against the industry’s 7.8% growth. ALGN’s earnings outpaced estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 7.8%.
Integra LifeSciences, carrying a Zacks Rank #2 (Buy), has an earnings yield of 13.6% against the industry’s negative 3.5% yield. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 16.7%. IART shares have rallied 48.3% against the industry’s 6.4% decline over the past year.
